

## Programmable One-Pot Oligosaccharide Synthesis

Zhiyuan Zhang, Ian R. Ollmann, Xin-Shan Ye, Ralf Wischnat, Timor Baasov,<sup>†</sup> and Chi-Huey Wong\*

Contribution from the Department of Chemistry and the Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037

Received June 26, 1998

**Abstract:** In an effort to develop a broadly applicable approach to the facile one-pot synthesis of oligosaccharides, the reactivity of a number of *p*-methylphenyl thioglycoside (STol) donors which are either fully protected or have one hydroxyl group exposed has been quantitatively determined by HPLC. We have characterized and quantified the influence on reactivity of the structural effects of different monosaccharide cores and different protecting groups on each glycoside donor. In addition, we have established a correlation between glycosyl donor reactivity and the chemical shift of the anomeric proton by <sup>1</sup>H NMR. Using the reactivity data, we have created a database of thioglycosides as glycosyl donors and demonstrated its utility in the easy and rapid one-pot assembly of various linear and branched oligosaccharide structures. In addition, we have developed the first computer program, OptiMer, for use as a database search tool and guide for the selection of building blocks for the one-pot assembly of a desired oligosaccharide or a library of individual oligosaccharides.

### Introduction

Carbohydrates are ubiquitous in biological systems, involved in such important functions<sup>1</sup> as inflammation,<sup>2</sup> immunological response,<sup>2d,3a–c</sup> metastasis,<sup>3d</sup> and bacterial and viral infection.<sup>1a</sup> While the synthesis of peptides and oligonucleotides was automated decades ago, there are no such general synthetic procedures available for the construction of complex oligosaccharides.<sup>4</sup> The necessity for regio- and stereocontrol in glycoside bond-forming processes often leads to laborious synthetic transformations, tremendous protecting group manipulations, and tedious intermediate isolations which complicate the overall synthetic process and decrease synthetic efficiency.

To facilitate the rapid synthesis of oligosaccharides, a new chemoselective glycosylation strategy, the “one-pot sequential glycosylation”, has recently been developed.<sup>5</sup> This approach is based on the observation that a large disparity between the reactivities of different glycosyl donors can be achieved simply by varying the protecting groups and the electron-donating or

-withdrawing character of the leaving group within a given class of glycosyl donors (e.g., thioglycosides). As a result, even though identical chemistry is performed at each glycosidic coupling step, with proper planning a high degree of sequence selectivity can be achieved between competing donors of the same class, eliminating the need for protecting group manipulation between coupling steps. The synthetic approach is designed such that the choice of protecting groups on sugar components,<sup>5a–c</sup> or the combination of protecting groups and anomeric substituent,<sup>5d,e</sup> will lead to a decrease in donor reactivity over the course of the synthetic sequence. The most reactive donor is used for the nonreducing end, and an unreactive donor is used for the reducing end of the given oligosaccharide target.

Using these procedures, multiple coupling steps were successfully performed by many laboratories to generate various lengths of complex oligosaccharides.<sup>5,6</sup> This methodology is, however, not generally applicable because of the lack of precise reactivity values of useful glycosyl donors and acceptors.<sup>7</sup> A particularly desirable goal in this research is to establish a generally applicable method that will allow the rapid synthesis of desired oligosaccharides from designed monomeric building blocks in a programmable and predictive manner. Such a method

<sup>†</sup> On sabbatical leave from the Department of Chemistry, Technion, Haifa, Israel 32000.

(1) (a) Varski, A. *Glycobiology* **1993**, *3*, 97. (b) Sharon, N.; Lis, H. *Sci. Am.* **1993**, *268* (1), 74.

(2) (a) Phillips, M. L.; Nudelman, E.; Gaeta, F. C. A.; Perez, M.; Singhal, A. K.; Hakomori, S.; Paulson, J. C. *Science* **1990**, *250*, 1130. (b) Lasky, L. A. *Science* **1992**, *258*, 964. (c) Giannis, A. *Angew. Chem., Int. Ed. Engl.* **1994**, *33*, 178. (d) Varski, A. *Proc. Natl. Acad. Sci. U.S.A.* **1994**, *91*, 7390. (e) Yuen, C.-T.; Bezouska, K.; O'Brien, J.; Stoll, M.; Lemoine, R.; Lubineau, A.; Kiso, M.; Hasegawa, A.; Bockovich, N. J.; Nicolaou, K. C.; Feizi, T. *J. Biol. Chem.* **1994**, *269*, 1595.


(3) (a) Ryan, C. A. *Proc. Natl. Acad. Sci. U.S.A.* **1994**, *91*, 1. (b) Meldal, M.; Mouritsen, S.; Bock, K. In *Carbohydrate Antigens*; Garegg, P. J., Lindberg, A. A., Eds.; ACS Symposium Series 519; American Chemical Society: Washington, DC, 1993; p 19. (d) Feizi, T. *Curr. Opin. Struct. Biol.* **1993**, *3*, 701.

(4) For recent review articles on oligosaccharide synthesis, see: (a) Paulsen, H. *Angew. Chem., Int. Ed. Engl.* **1990**, *29*, 823–839. (b) Banoub, J. *Chem. Rev.* **1992**, *92*, 1167–1195. (c) Toshima, K.; Tatsuta, K. *Chem. Rev.* **1993**, *93*, 1503. (d) Schmidt, R. R.; Kinzy, W. *Adv. Carbohydr. Chem. Biochem.* **1994**, *50*, 21. (d) Danishefsky, S. J.; Bilodeau, M. T. *Angew. Chem., Int. Ed. Engl.* **1996**, *35*, 1380.


(5) (a) Fraser-Reid, B.; Udodong, U. E.; Wu, Z.; Ottosson, H.; Merritt, J. R.; Rao, C. S.; Roberts, C. *Synlett* **1992**, 927. (b) Raghavan, S.; Kahne, D. *J. Am. Chem. Soc.* **1993**, *115*, 1580. (c) Yamada, H.; Harada, T.; Miyazaki, H.; Takahashi, T. *Tetrahedron Lett.* **1994**, *35*, 3979. (d) Yamada, H.; Harada, T.; Takahashi, T. *J. Am. Chem. Soc.* **1994**, *116*, 7919. (e) Chenault, H. K.; Castro, A. *Tetrahedron Lett.* **1994**, *35*, 9145. (f) Ley, S. V.; Priepke, H. W. M. *Angew. Chem., Int. Ed. Engl.* **1994**, *33*, 2292. (g) Grice, P.; Ley, S. V.; Pietruszka, J.; Priepke, H. W. M.; Walther, E. P. E. *Synlett* **1995**, 781. (h) Geurtsen, R.; Holmes, D. S.; Boons, G.-J. *J. Org. Chem.* **1997**, *62*, 8145. (i) Grice, P.; Ley, S. V.; Pietruszka, J.; Osborn, M. I.; Henning, W. M.; Priepke, H. W. M.; Warriner, S. L. *Chem. Eur. J.* **1997**, 431.

(6) Green, L.; Hinzen, B.; Ince, S. J.; Langer, P.; Ley, S. V.; Warriner, S. L. *Synlett* **1998**, 4, 440.

(7) For quantitative analysis of the glycosylation reactivity of several glycosyl donors using NMR, see the leading work: Douglas, N. L.; Ley, S. V.; Lucking, U.; Warriner, S. L. *J. Chem. Soc., Perkin Trans. 1* **1998**, 51.

**Scheme 1.** Strategy for One-Pot Synthesis of Linear and Branched Oligosaccharides<sup>a</sup>

<sup>a</sup> X represents the *p*-methylphenylthio group.

**Scheme 2**

can be used in the rapid assembly of complex oligosaccharides and may be further developed toward automation.

As a first step toward this goal, we report here a general procedure for the quantitative measurement of relative reactivities of various glycosyl donors and acceptors using HPLC. Employing this methodology, up to 50 different donor and acceptor molecules, comprising six different monosaccharide skeletons and 11 commonly used protecting groups, have been evaluated. For each structure, a relative reactivity value (RRV) is determined. With this relative reactivity database in hand, we have developed a general computer program compatible with Macintosh computers which can search the database to identify optimal combinations of glycosyl building blocks. This strategy enables the automated design of a rapid, one-pot synthetic protocol for the synthesis of linear and branched oligosaccharides (Scheme 1).

## Results and Discussion

**General Strategy.** As a first step to this investigation, the following questions were examined: (1) what is the best choice of leaving group at the anomeric center of glycosyl donor, (2) what promoter system will be most appropriate for the coupling reaction, which is sufficiently general to handle a wide variety of glycosyl donors and acceptors, and (3) what methodology should be used to rapidly and accurately assess the reactivities of different glycosyl donors?

Among the commonly used leaving groups, we chose thioglycosides<sup>8</sup> as "universal building blocks" because they are stable under most reaction conditions frequently used for the construction of building blocks. They can be activated by various conditions such as NIS-TfOH,<sup>9a,b</sup> MeOTf,<sup>9c</sup> DMTST,<sup>9e</sup> IDCP,<sup>9f</sup> Selectfluor,<sup>9g</sup> and other promoters.<sup>8</sup> The characteristic high UV absorbency of the *p*-methylphenylthio (STol) group (for example, for *p*-methylphenyl mercaptan<sup>10</sup> in MeOH at  $\lambda = 256$  nm,  $\epsilon = 5 \times 10^4$  M<sup>-1</sup> cm<sup>-1</sup>) facilitates the precise quantification of the reactivities of glycosyl donors. In addition, thioglycosides with one hydroxy group as acceptor as well as donor are easily prepared, and thioglycosides are readily converted to other glycosyl donors commonly used in oligosaccharide synthesis, including sulfoxides,<sup>11</sup> fluorides,<sup>9g,12</sup> and halides.<sup>13</sup> Finally, accessible alternative glycosylation chemistries may later allow

for the use of several different donor types in a cooperative fashion as part of an orthogonal coupling strategy.<sup>14</sup> We chose NIS-TfOH as the main promoter for this study. It is a stoichiometric reagent and suitable for a variety of thioglycosides.

Our approach to the quantification of glycosyl donor reactivities is based on earlier works by Sinnott<sup>15</sup> and Fraser-Reid et al.,<sup>16</sup> which employ a competition reaction between two donors to determine the relative rates of reactivity between them. The overall competition reaction is thought to proceed as shown in Scheme 2. Two glycosyl donors **A**<sub>1</sub> and **A**<sub>2</sub> are forced to compete in a reversible fashion for a common electrophile (E<sup>+</sup>), forming activated intermediates **B**<sub>1</sub> and **B**<sub>2</sub>. These intermediates may collapse to the corresponding transient oxocarbenium cations **C**<sub>1</sub> and **C**<sub>2</sub>, which then rapidly react with the acceptor molecule to give the products. Assuming that the rate-determining step is the step **B** → **C**, the overall reaction can be described by an apparent second-order rate constant, rate =  $k_{\text{obs}}[\text{E}^+][\text{A}]$ . This is related to the first-order rate equation (rate =  $k[\text{C}]$ ) by the relation,  $k_{\text{obs}} = k/K$ . Our measured rate constants,  $k_{\text{obs}}$ , are relative second-order rate constants, not absolute quantities. Measuring the rates as relative values allows us to escape rate dependence on the identity of the activator. To the extent that **B** → **C** remains the rate-determining step and the

(8) For a recent review on the synthesis and application of thioglycosides, see: Garegg, P. J. *Adv. Carbohydr. Chem. Biochem.* **1997**, 52, 179.

(9) (a) Konradsson, P.; Udodong, U. E.; Fraser-Reid, B. *Tetrahedron Lett.* **1990**, 31, 4313. (b) Veeneman, G. H.; van Leuwen, S. H.; van Boom, J. H. *Tetrahedron Lett.* **1990**, 31, 1331. (c) Lonn, H. *Carbohydr. Res.* **1989**, 135, 105. (d) Garegg, P. J. *Acc. Chem. Res.* **1992**, 25, 1167. (e) Fugedi, P.; Garegg, P. J. *Carbohydr. Res.* **1986**, 149, C9. (f) Veeneman, G. H.; van Boom, J. H. *Tetrahedron Lett.* **1990**, 31, 275. (g) Burkart, M. D.; Zhang, Z.; Hung, S.-C.; Wong, C.-H. *J. Am. Chem. Soc.* **1997**, 119, 11743.

(10) Pinkernell, U.; Karst, U.; Cammann, K. *Anal. Chem.* **1994**, 66, 2599.

(11) Kahne, D.; Walker, S.; Cheng, Y.; Van Engen, D. *J. Am. Chem. Soc.* **1993**, 115, 1580.

(12) (a) Mukayama, T.; Murai, Y.; Shoda, S. *Chem. Lett.* **1981**, 431. (b) Nicolaou, K. C.; Dolle, R. D.; Papahatjis, D. P.; Randall, J. L. *J. Am. Chem. Soc.* **1984**, 106, 4189.


















































(13) (a) Sato, S.; Mori, M.; Ito, Y.; Ogawa, T. *Carbohydr. Res.* **1986**, 155, C6. (b) Anderson, F. O.; Fugedi, P.; Garegg, P. J.; Nashed, M. *Tetrahedron Lett.* **1986**, 27, 3919.

(14) Ito, Y.; Ogawa, T. *J. Am. Chem. Soc.* **1994**, 116, 12073.

(15) Sinnott, M. L. *Chem. Rev.* **1990**, 90, 1171.

(16) Fraser-Reid, B.; Wu, Z.; Udodong, U. E.; Ottosson, H. *J. Org. Chem.* **1990**, 55, 6068.

**Table 1.** Relative Reactivity Values of Thioglycosides<sup>a</sup>

 1 (1.0)	 8 (5.7)	 16 (19.2)	 24 (118.7)	 31 (254.3)	 38 (731.4)	 44 (2797)
 2 (1.0)	 9 (7.9)	 17 (20.0)	 25 (142.9)	 32 (268.6)	 39 (780.0)	 45 (3531)
 3 (1.3)	 10 (9.4)	 18 (24.1)	 26 (148.6)	 33 (285.7)	 40 (1155)	 46 (7180)
 4 (1.7)	 11 (10.4)	 19 (28.9)	 27 (162.9)	 34 (320.0)	 47 (8417)	 48 (1.7x10 <sup>4</sup> )
 5 (2.7)	 12 (11.4)	 20 (31.4)	 28 (182.9)	 35 (340.1)	 41 (1320)	 49 (2.0x10 <sup>4</sup> )
 6 (4.1)	 13 (13.1)	 21 (57.3)	 29 (185.4)	 36 (482.9)	 42 (1791)	 50 (7.2x10 <sup>4</sup> )
 7 (5.7)	 14 (14.3)	 22 (67.1)	 30 (208.6)	 37 (577.1)	 43 (2656)	 50 (7.2x10 <sup>4</sup> )

<sup>a</sup> This table was constructed on the basis of the manner shown in Chart 1. The relative reactivity value (RRV) of the most unreactive compound, acetylated mannoside, was defined as 1.0. Compounds are numbered as the decreased reactivity trend, and the RRVs are shown in parentheses.


mechanism is the same, this should help ensure that the relative rates measured here will remain useful for many different activators and perhaps other donor types as well. This analysis is also true for glycosyl donors with neighboring group participation, which occurs after the rate-determining step.

**Construction of the General Reactivity Database.** Table 1 was constructed by comparison of reactivities between the various glycosyl donors and a small set of reference compounds (7, 14, 33, and 48). The relative reactivities between the four reference compounds were also examined. Based on these data, the relative reactivities of all 50 compounds were quickly determined through simple multiplication of the relative rate constant ratios with the reference compounds. Since these values are relative, they are normalized such that the least reactive donor in the library has a reactivity of 1.0 (Chart 1).

The individual RRVs which were used to make the table were determined by a direct competition assay. Unlike the previous works,<sup>7</sup> however, we did not directly obtain relative rate ratios from ratios of product formation. While it is possible to directly measure a relative first-order rate constant by a competition assay between two donors using a large excess of reagents **A** over activator **E**<sup>+</sup> (Scheme 2), such that the donor (**A**) concentrations do not change appreciably over the course of the reaction, these methods did not immediately lend themselves to HPLC analysis in our case. Since we followed the reaction by disappearance of the donor rather than appearance of product (see Experimental Section), arranging the experiment so that pseudo-first order kinetics are observed is relatively different.


**Chart 1<sup>a</sup>**

$$\text{RRV (40)} = 4.04 \times 20.0 \times 14.3 = 1155$$




<sup>a</sup> The arrows indicate the deactivation direction. Numbers on the arrows are the experimental relative reactivity ratios, and the numbers in parentheses are the calculated RRVs.

To enhance the sensitivity of the experiment, we chose to allow a significant portion of the donors to be consumed. 1:1:1 stoichiometries of **A**<sub>1</sub>:**A**<sub>2</sub>:**E**<sup>+</sup> in the presence of 5 equiv of acceptor (methanol) were used. The integrated second-order rate



**Figure 1.** Example of the relative reactivity measurement between a thioglycoside ( $D_x$ ) and the reference compound ( $D_{ref}$ ) by using HPLC (see Experimental Section for details). The intensity of absorbance at 256 nm for each remaining donor was measured to determine the relative reactivity ( $k_x/k_{ref}$ ).  $[D]_t$ , donor concentration at time  $t$ ;  $(A)_t$ , donor absorbance at time  $t$ .

**Table 2.** Accuracy Measurement of Calculated Relative Reactivities<sup>a</sup>



<sup>a</sup> The relative reactivity ratios obtained from experiment are shown without parentheses. The calculated ratios are shown in parentheses. The arrow indicates the direction of decreased reactivity.

equations from Scheme 2 give the relationship between relative rate constant ratios and donor concentrations, as shown in eq 1. A typical HPLC analysis of relative reactivities in a competition experiment is shown in Figure 1.

$$\frac{k_{obs,1}}{k_{obs,2}} = \frac{\ln([A_{1,t}]/[A_{1,0}])}{\ln([A_{2,t}]/[A_{2,0}])} \quad (1)$$

The internal self-consistency of these measurements was determined by examining a series of relative rate constants (Table 2). Comparing the experimental data and calculated data for each pair shows that the average error is about 10%. This accuracy should be sufficient for the use of these data library for guiding one-pot oligosaccharide syntheses.

In addition, we were interested in how different promoters will affect the reactivities of glycosyl donors. We measured the relative reactivities between two pairs of donors, **14** vs **11** and **7** vs **5**, with two promoter systems, NIS-TfOH and DMTST. The observed RRVs were approximately the same in both promoter systems:  $k_{14}/k_{11} = 1.4$  (NIS-TfOH) and 1.4–2.0 (DMTST), and  $k_7/k_5 = 2.0$  for NIS-TfOH and 1.3–1.7 for DMTST.<sup>17</sup> These preliminary results suggest that different promoters do not dramatically affect the relative reactivities of glycosyl donors. Thus, the RRVs in Table 1 may also be

**Table 3.** Competition Reactions between Perbenzylated and Peracetylated Thioglycosides of Different Monosaccharides<sup>a</sup>

<b>A</b>			
	<b>50</b> (27.1)	<b>48</b> (6.4)	<b>43</b> (1.0)
<b>B</b>			
	<b>21</b> (57.3)	<b>14</b> (14.3)	<b>11</b> (10.4)
	<b>5</b> (2.7)	<b>4</b> (1.7)	<b>1</b> (1.0)

<sup>a</sup> Relative reactivity ratios are shown in parentheses. The reference donors are in a box. The RRVs shown were normalized based on **48** (A) and **1** (B).

applicable to other promoters as well. We have taken advantage of this fact, employing DMTST in a one-pot oligosaccharide synthesis (see One-Pot Synthesis of Oligosaccharides, below) as a solution to the problem of byproduct participation in the glycosylation reaction when NIS is used as an activator.

**Structural Effects of Monosaccharides on the Anomeric Glycosylation Reactivity.** The completion of Table 1 allows us to examine the influence of stereochemistry and identity of different substituents on the anomeric reactivity of various types of glycosyl donors. From the results in Table 3, it is clear that the most reactive sugar is fucose, followed by galactose, glucose, and mannose (Table 3A). Perbenzylated fucose **50** is 4.2-fold more active than perbenzylated galactose **48**, and the latter is 6.4-fold more active than perbenzylated glucose **43**. The higher reactivity of the fucoside is probably because the  $-\text{CH}_3$  group is more highly electron donating than the  $-\text{CH}_2\text{OBn}$  group. The reactivity order of different sugar cores appears to remain very similar when the experiments are performed with different types of protecting groups. For example, when peracetylated galactose **14** (Table 3B) was competed against peracetylated glucose **5**, the ratio of 5.3 in favor of galactose **14** was obtained. The higher reactivity of the galactoside than the glucoside has been reported in the study of hydrolysis of glycosyl halides<sup>18</sup> and glycosides.<sup>19</sup> It presumably arises due to the stereo and inductive effects and possible involvement of the axial 4-O lone-pair electrons in the stabilization of the oxocarbenium ion intermediate.<sup>19</sup> Based on the results in Table 3, the reactivity order of monosaccharides appears to be fucose > galactose > glucose > mannose.


Since amino sugars are widely found in natural systems and provide very distinct electronic and structural features, we wanted these important systems to be included in our investigation. Initially, we selected the most abundant glucosamine and

(17) A precise measurement with DMTST is difficult as its efficiency for the activation is lower than that of NIS; normally 4 equiv of DMTST is used for the glycosylation and the reaction is much slower than that of NIS. We observed that 2 equiv could be enough to complete a reaction with 1 equiv of thioglycoside within a certain time. For the competition reactions, the conditions were exactly the same as those with NIS-TfOH (see general procedure in Experimental Section), except that DMTST was taken as 2 mole equiv relative to the donors (each 1 mole equiv) and the reaction was continued for 3 h. This measurement can only be performed between donors with small reactivity differences.

(18) Paulsen, H. *Angew. Chem., Int. Ed. Engl.* **1982**, *21*, 155.

(19) Miljkovic, M.; Yeagley, D.; Deslongchamps, P.; Dory, Y. L. *J. Org. Chem.* **1997**, *62*, 7597.



**Table 4.** Effect of C-2 Substitution on the Reactivity of Thiogalactoside Donors: RRVs for 4,6-O-benzylidene Derivatives<sup>a</sup>

<sup>a</sup> Competition reactions were performed between 2-*O*-benzylgalactoside **29** as a reference and each of the other compounds in this table. The RRVs were calculated on the basis of **18**. The focal substituents for the study are shown in bold.

galactosamine cores. The phthalyl group keeps the above trend of the reactivity difference between galactose and glucose structures (the reactivity of *N*-phthalyl galactose **11** is 6.1-fold higher than that of *N*-phthalyl glucose **4**); the unusually high reactivity of trichloroethyl oxycarbonyl (Troc) group protected amines was very surprising. For example, the *N*-Troc-protected glucosamine **21** (Table 3B) is 33.7-fold more reactive than the corresponding *N*-phthalyl-protected glucosamine **4**. Furthermore, glucosamine **21** becomes even more reactive (5.5-fold) than the corresponding galactosamine **11**, in which the amine is protected with a phthalyl group. This observation<sup>20</sup> is particularly important in terms of regulating the relative reactivities of aminoglycoside donors for the assembly of a target compound with a 2-amino sugar either at (or close to) the nonreducing end or at (or close to) the reducing end.

**Effect of Protecting Groups on the Reactivity of Thioglycoside Donors.** The effect of substituents on the reactivity at the anomeric center has been long recognized.<sup>21</sup> Glycosyl donors with ester protecting groups undergo glycosylation reactions much more slowly than do the corresponding donors with ether protection. The reason for this phenomenon is that the electron-withdrawing character of the ester group destabilizes the putative cationic transition state, leading to glycoside formation.<sup>21c</sup> Recently, Ley and co-workers have provided the first systematic quantitation of such an effect by comparing the reactivity differences between benzoate and benzyl groups on rhamnosyl and mannosyl donors.<sup>7</sup> In our hands, this effect seems to be one of the most pervasive and consistent determinants of glycosyl reactivity.


The data presented here allow detailed examination of the activation or deactivation of a series of glycosyl core structures in conjunction with a number of different protecting groups at the 2-position. Within the specific confines of the galactosyl

(20) The elevated reactivity of *N*-Troc-protected glucosamines might be the result of the electron-donating property of the *N*-trichloroethoxycarbonyl group to stabilize the intermediate as shown in the following tentative mechanism. Research is underway to test the proposal.



For an accelerated acetylation of 2-AcNH glucoside in acetic acid, see: Cocker, D.; Sinnott, M. L. *J. Chem. Soc., Perkin Trans. 2* **1976**, 618.

(21) (a) Feather, M. S.; Harris, J. F. *J. Org. Chem.* **1965**, *30*, 153. (b) Capon, B. *Chem. Rev.* **1969**, *69*, 407. (d) Fraser-Reid, B.; Boctor, B. *Can. J. Chem.* **1969**, *47*, 393. (e) Paulsen, H.; Richter, A.; Sinnwell, H.; Stenzel, W. *Carbohydr. Res.* **1974**, *38*, 312.

**Table 5.** Positional Effects of Benzoyl versus Hydroxyl Group on the Reactivities of Thiogalactoside Donors<sup>a</sup>


<sup>a</sup> Competition reactions were performed between perbenzylated galactoside **7** and each of the other compounds in this table. RRVs were calculated on the basis of **7**. The substituents of interest are shown in bold.

core (Table 4), for example, we can conclude that the deactivating power of different electron-withdrawing groups is in the order of  $-N_3 > -OClAc > -NPhth > -OBz > -OBn$ .

**Effects of the Electron-Withdrawing Group Position.** The reactivity perturbation arising from the exchange of one protecting group for another was found to be highly dependent on the position of the protecting group around the glycosyl core, as well as the identity of that core. The first effect can be demonstrated by comparing the reactivity of sugars with a benzoyl protecting group versus those with a hydroxyl group at the same position (Table 5). Removal of the benzoyl group from the 4-*O* position causes the largest increase in the rate of reaction. This was, however, not seen for other pyranoses, for which the protecting group at the 2-position has been found to be more important.<sup>7</sup> This might be explained by the participation of 4-oxygen of galactose in the stabilization of the putative cationic transition state.<sup>18</sup> The observed stronger effect of C3-OH relative to that of C2-OH might be explained by its close association with the substituent at the 4-position. In addition to the destabilization of the presumed cationic transition state through inductive effects, benzylation of the 3-position may also diminish the participation of the lone-pair electrons of C-4 oxygen in the stabilization of the cationic transition state. From Table 5, the observed influence of the positions of the benzoate group is in the order of  $4 > 3 > 2 > 6$ . These results are different from those observed for the mannose system, in which the order of  $2 > 6 > 4 > 3$  was determined.<sup>7</sup> In the latter case, except for the neighboring 2-position, the proximity of the benzoate to the ring oxygen was found to be more important than its distance from the anomeric position.

The results presented in Table 5 also provide, for the first time to our knowledge, a direct reactivity comparison between the protecting group and the hydroxyl group in the same position. Such data are of particular importance for the design of highly chemoselective one-pot glycosylation sequences (Scheme 1), in which the acceptor molecule in one step becomes the donor in the following step.<sup>5</sup> Therefore, the reactivity measurements of glycoside donors that also contain one free hydroxyl group are crucial for the successful accomplishment of such a challenging task. For this purpose, we have examined and broadly quantified the influence of various protecting groups and monosaccharide type on the reactivity of monohydroxy glycosides as donors (Tables 5–7).

It should also be noted that the reactivity of 4,6-benzylidene-protected galactose derivatives that have a free 3-OH group (structures in Table 6A) is influenced by C-2 protecting groups in the same manner as when the 3-OH was protected. Thus, the deactivating effects of different groups at the C-2 position

**Table 6.** Effect of a Series of Different Protecting Groups on the Ability of Monohydroxy Thioglycosides To Serve as Donors<sup>a</sup>

<sup>a</sup> The competition reactions were performed between benzylidene galactoside **33** as a reference and each of the compounds. The RRVs shown were normalized on the basis of **34** (A) and **8** (B). The substituents of interest are shown in bold.


are in the same order ( $-\text{OCIAc} > -\text{OBz} > -\text{OBn}$ ) as was observed from the 3-OCIAc-protected galactoside derivatives in Table 5. However, *the magnitude of the deactivating effects is significantly dependent on the identity of the other protecting groups on the molecule.* For example, while benzoate protection at the 2-position caused the galactoside **24** to be 1.6 times less reactive than the benzyl group in the same position (**29**, Table 4), the same comparison between benzoate and benzyl systems in 3-hydroxyl-free galactosides **42** and **49** (Table 6A) gave a factor of 11.2. A similar inconsistency in the deactivation power is seen for the pair 2-OAcCl (**20**) and 2-OBn (**29**) when the 3-position was protected (5.9-fold difference, Table 4) or free (62.5-fold difference between **34** and **49** in Table 6A). Thus, there are not consistent quantifiable reactivity trends which lend themselves to a simple numerical reactivity model. Though there exist consistent qualitative trends (e.g.,  $-\text{OBn}$  is less deactivating than  $-\text{OBz}$ ), the degree of this influence appears to be highly dependent upon the structure of the rest of the molecule. As a result, we have taken the approach of directly measuring the relative reactivity of each donor that enters our library.

**Effect of Glycosylation on Donor Reactivity.** Glycosylation of a free hydroxyl has a slight deactivating effect on the anomeric reactivity of the acceptor. This is significant, as for the second and later steps, the reactivity of the growing oligosaccharide reducing end generally has not been explicitly characterized. Fortunately, the deactivating effect of glycosylation is typically small in most cases relevant to the synthesis. This issue was examined on a series of different structures, and the results are shown in Table 7. In general, the results show that glycosylation of the hydroxyl function of a given monohydroxy sugar causes a small decrease in reactivity. Glycosylation by a perbenzylated sugar causes a decrease in reactivity by a factor of 1.1–2.3, depending on the position of glycosylation, while glycosylation by a perbenzoyleated sugar caused a more significant decrease in reactivity (a factor of 9.4 for **2**  $\rightarrow$  **10**). A somewhat larger deactivating effect from perbenzylated sugars when glycosylating the 2-position of the acceptor was observed in one case (a factor of 4.5 for **45**  $\rightarrow$  **39**). This may be the result of significant steric effect on the anomeric center. It seems that the degree of deactivation introduced by the glycosyl structure varies with the reactivities of the glycosyl donors. Less reactive glycosyl donors are more strongly deactivating once the glycosyl linkage is formed.


Fortunately, in the context of the synthetic methodology developed here, the glycosylation reactions that have the most impact on the anomeric reactivity of the acceptor are those that are the most electron withdrawing—those that tend to come at the very end of the synthetic route. The largest deactivation will occur on the last donor. Since the reducing end is typically expected to be an unreactive glycoside such as a methyl glycoside, there is no competing reaction at the step when it is appended to the oligosaccharide chain, and so deactivation is not expected to be a problem at that step. Thus, the worst relevant reactivity shifts due to glycosylation will occur upon glycosylation of the third residue from the reducing end by the fourth residue from the reducing end. In cases of syntheses of tetra-, penta-, or hexasaccharides, the fourth residue from the reducing end is expected to be reasonably active. Therefore, its deactivating effect is not likely to be large, even in the worst of cases for targets of this size. However, it should be noted that, in extended synthetic schemes, it would likely be prudent to leave a larger reactivity window between donors at the last steps of the reaction sequence to account for glycosylation-associated deactivation.

**Correlation between Chemical Shift of Anomeric Proton NMR and  $\ln(\text{RRVs})$ .** During the study of thioglycoside reactivity, we have observed that the chemical shift of the anomeric proton of the more active perbenzylated thioglycoside **48** is remarkably farther upfield than the less active perbenzoyleated analogue **7** ( $\delta = 4.58$  ppm vs  $\delta = 4.98$  ppm). Interestingly, when we examined some compounds which have the same protecting group ( $-\text{OBz}$ ) at the C-2 position on the same core structure (e.g., galactose), we observed a good linear correlation between the chemical shifts of the anomeric protons and the corresponding  $\ln(\text{RRVs})$  (Figure 2). Compounds with different protecting groups at the C-2 position do not show a good correlation, probably due to different shielding effects or other unknown mechanisms. Since the stability of the glycosylation transition state appears to be largely influenced by the electron density of the anomeric center, the chemical shift of the anomeric proton might be used to rapidly determine the anomeric reactivities in certain cases.

**Prediction of Optimal Donor Reactivities.** Notwithstanding the appearance of unwanted side reactions and other effects which detract from the yield of all glycosylation reactions, the highest yielding glycosylation steps will be those which have the greatest difference in anomeric reactivity between the donor and the acceptor. Thus, a high-yielding multistep procedure is one which will employ the largest reactivity difference at each step. As a result, those donors which are destined to react in the first coupling step should be drawn from the pool of the most reactive donors available, and those which are destined to react at the last coupling step should be drawn from the pool of least reactive available donors. The logarithmic nature of eq 1 implies that there is a strongly diminishing return in yield to be gotten from increasing the ratio of relative anomeric reactivities of the donor and acceptor at a given step. Thus, reducing the ratio of relative rates for one step so as to increase it for another will result in a sizable loss in overall yield, unless the ratio in the first step was larger than that of the second to begin with. Thus, it should be evident that, for optimal yield, the ratio of reactivities between donor and acceptor should be the same (and as large as possible) for each step. The principle of constant rate ratios allows us to predict that the optimum relative reactivity value ( $k_x$ ) to be used at each step  $x$  in a sequence of  $N$  steps is given by eq 2.  $k_1$  is the relative reactivity

**Table 7.** Effect of Sugar Substitution on the Reactivity of a Monohydroxy Thioglycoside<sup>a</sup>

<sup>a</sup> RRVs are given in parentheses. The arrows indicate pairs of compounds to be compared.

**Figure 2.** Relation between the chemical shifts of the anomeric protons of thioglycosides and their  $\ln$ RRVs.

constant of the donor to be used in the first step.  $k_N$  is the relative reactivity constant of the donor to be used in the  $N$ th step.

$$k_x = k_1 \left( \frac{k_N}{k_1} \right)^{(x-1)/(N-1)} \quad (2)$$


**Computational Approach.** Since exactly the right donor reactivity as predicted by eq 2 is not always available for every step, we generated a computer program that can search the donor library for the best sets of available donors, allowing for the programmed assembly of oligosaccharides. The program, named OptiMer, interfaces with a database of donors (data from Table 1) stored using the FileMaker Pro 4.0 (FileMaker Inc.) database program. The database stores the type of sugar core that it contains, the location of any unprotected hydroxyls that may be glycosylated, and the  $\alpha$ - or  $\beta$ -directing nature of the substituent at the 2-position, which is used to predict the product stereochemistry at the anomeric carbon. OptiMer considers all this information when examining sequence combinations. In addition, the database also stores a picture of the compound, its name, and a reference to the literature where the preparation of the donor is described. Once given a target sequence (e.g., DGal $\alpha$ 1,4DGlcN $\beta$ 1,6DGal $\beta$ 1,4DGlc) the program searches the

in-house database to identify the 100 best sets of available characterized oligosaccharide donors (see Figure 2 as an example). For large sequences, a Monte Carlo search method is also available, which simply tests combinations at random. The frequency with which each donor appears at each step in the list of the best 100 donor sets is tabulated, and the user is presented with a list of donors at each step which tend to give the highest overall yields (Figure 3). The chemist is then free to make an educated choice as to which donors to use on the basis of availability, cost, and knowledge of the optimal mathematical relationships between donor reactivities as detailed above. We believe this program will become very useful when the number of building blocks is expanded.

**One-Pot Synthesis of Oligosaccharides.** With this database and the computer program in hand, we then performed the one-pot synthesis of several tri- and tetrasaccharides (Schemes 3 and 4). The building blocks were added sequentially in order of their decreasing RRVs. Scheme 3 illustrates the synthesis of linear trisaccharides **52**, **53**, and **54**. The overall yield of each trisaccharide synthesis is around 60%, which corresponds to about 80% yield of each coupling step. Trisaccharide **52** contains both  $\alpha$ - and  $\beta$ -glycosidic linkages and was prepared with the donor **48** being active and the acceptor **19** being inactive. Indeed, according to their RRVs, perbenzylated **48** is 588-fold more reactive than the benzoylated **19**. However, the syntheses of trisaccharides **53** (Scheme 3b) and **54** (Scheme 3c) could not be performed without quantitative information on the RRVs of the appropriate donor and acceptor molecules. In the synthesis of **53**, we first employed the relatively activating N-Troc protecting group for 2-aminoglycosides. The 2-N-Troc-protected thioglycoside **21** is 4.4-fold more active than the benzoylated galactoside **13**. This difference in RRVs was sufficient to perform the one-pot synthesis of trisaccharide **53** in the overall yield of 56%.

The synthesis of trisaccharide **54** (Scheme 3c) demonstrates the sequential construction of two  $\alpha$ -glycosidic bonds in a one-pot manner. The thioglycosides used in this synthesis are **50** and **49**, and the difference in their RRVs is only 3.6-fold. To increase the selectivity of the coupling step, the donor **50** was used with 1.5 equiv, and the reaction was performed with the promoter DMTST. The results in Scheme 3 demonstrate that the RRVs database can be sufficiently applied not only for NIS-TfOH-promoted reactions but also for the DMTST-promoted





**Figure 3.** Picture of the OptiMer program in operation. In the background on the left is a FileMaker Pro database which contains the donor library. Upon hitting the “Run Search” button, OptiMer launches and then presents the user with a dialogue box requesting the target oligosaccharide sequence (foreground). The results appear in the remaining window as a list of donor sequence “hits” accompanied by optimum yield calculations, and then a list of the frequency of donor appearance at each step from the top 100 hits (for use with large libraries). The chemist may opt to either take one of the best sequences found or select from the list of best donors at each position to design his own sequence on the basis of knowledge of donor availability or other desired properties.

glycosylations and may further be utilized for other promoters to activate thioglycosides.


To demonstrate the application of the relative reactivity donor database, we constructed two different tetrasaccharides, compounds **55** and **57** (Scheme 4), in a one-pot manner. In the synthesis of **55**, we used the reactivity differences of 104 (**48** → **27**) and 5.9 (**27** → **13**) for the first two glycosylation steps, respectively. While these reactivity differences were sufficient to synthesize the target tetrasaccharide **55** in an overall 40% yield (about 74% yield for each coupling step), it should be noted that the efficiency of this synthesis is much lower than is predicted by the OptiMer search (82%, see Figure 2). Two main reasons for this high discrepancy between the theoretical and experimental results are immediately apparent. One reason is that, at this stage of the development, the OptiMer program does not consider the possibility of the occurrence of side reactions (e.g., decomposition reactions) and the deactivation introduced by the newly formed glycosyl bond. Thus, the reaction yields reported by OptiMer should be considered yield optima, analogous to a 100% yield in a normal reaction.

The second main reason relates to the promoter system NIS-TfOH. When using NIS-TfOH, an equimolar amount of succinimide is generated in the reaction mixture. Although the nitrogen of succinimide is a poor nucleophile, in the case of highly unreactive acceptors, it can compete effectively for the remaining pool of activated glycosyl donors. This is most important when the hydroxyl of the sugar acceptor is very hindered (e.g., 4-OH of glucose, 4-OH of galactose) or has a poor nucleophilicity (e.g., due to electron-withdrawing substituents in the vicinal position). Indeed, in several cases of the preparation of the disaccharide building blocks in Table 1, we have isolated and characterized the glycosyl succinimide products.<sup>23</sup> Moreover, since in the one-pot sequential synthesis

the succinimide accumulates from step to step, it may become especially problematic for the later steps, resulting in a significant decrease in the overall yield of the target glycosylation product. One way to avoid such problems is to use a combination of two promoter systems: DMTST and NIS-TfOH. Although DMTST is less active than NIS-TfOH and is not suitable for unreactive donors, it does not produce a nucleophile as a side product. It can be used at the initial steps of one-pot syntheses, which often contain very reactive thioglycosides. In later steps, which contain less reactive thioglycosides for which DMTST is no longer appropriate, the reaction can be promoted by NIS-TfOH, thereby diminishing the overall buildup of succinimide. This protocol was successfully employed for the assembly of the branched tetrasaccharide **57** (Scheme 4b). This work highlights the importance of further investigation into thioglycoside activators with nonnucleophilic byproducts.

Based on the orthogonal protection–deprotection strategy developed in our laboratory for the synthesis of a highly branched oligosaccharide library,<sup>22</sup> we have also demonstrated the possibility of combination of orthogonal protection–deprotection strategy and the one-pot sequential strategy in the synthesis of branched oligosaccharide. This combination pro-


(23) For example, in the synthesis of the lactoside **9** (see scheme below), in addition to the target disaccharide **9** (65%), the succinimide product **58** (15%) was also isolated as a byproduct.



The low reactivity of the 4-OH of glucoside **10** (RRV = 8.4), coupled with an increased reactivity of the transient intermediate cation derived from the initial reaction of galactoside **48** (RRV = 1776) with iodonium ion, could explain the formation of **57**.


(22) Wong, C.-H.; Ye, X.-S.; Zhang, Z. *J. Am. Chem. Soc.* **1998**, *120*, 7137.



**Scheme 3.** One-Pot Synthesis of Trisaccharides **52–54** Using Designed Building Blocks with Known RRVs (in Parentheses)

vides an efficient method for rapid assembly of highly branched oligosaccharide libraries, as shown in the construction of the branched tetrasaccharide **57** (Scheme 4b). We have prepared some orthogonally protected disaccharides thioglycoside analogues and studied their reactivities (Table 1). In the synthesis of the branched tetrasaccharide **57**, we first performed the reaction between **48** and **32** in the presence of NIS-TfOH and found that the reaction proceeds with very fast consumption of the donor to give exclusively the succinimide galactoside.<sup>23</sup> All the starting acceptor **32** could be recovered from this reaction mixture. We assume that the elevated reactivity of the donor **48** coupled with high steric hindrance of the secondary hydroxyl in **32** leads to a very efficient competition of succinimide to afford the byproduct.

To solve this problem, the reaction between **48** and **32** was performed with the use of DMTST as a coupling reagent (Scheme 4b). In these conditions, the reaction proceeded smoothly, and the product, without the isolation, was further treated with acceptor **56** in the presence of NIS-TfOH to afford **57** in a one-pot, two-step procedure (57% yield). Further investigation is underway in order to construct **57** from the corresponding monosaccharides in a one-pot manner by using a similar combination of NIS and DMTST. In addition, the strategy employed for the synthesis of tetrasaccharide **57** (Scheme 4b) might be a general strategy for the preparation of branched oligosaccharides library. The key of such an approach

**Scheme 4.** One-Pot Synthesis of Tetrasaccharides **55** and **56** Using Designed Building Blocks with Known RRVs (in Parentheses)

is the use of an orthogonally protected monosaccharide, such as galactoside **59**<sup>22</sup> and **35** (see Experimental Section). This sugar was selectively deprotected at each position to generate the corresponding monohydroxy sugars **25**, **36**, **44**, and **45**, carrying a free hydroxyl group at the 3-, 6-, 4-, and 2-position, respectively. Each of these compounds was glycosylated by the donor with higher RRV, to generate the corresponding disaccharides; for example, **25**  $\rightarrow$  **26**, **36**  $\rightarrow$  **30**, **44**  $\rightarrow$  **41**, and **45**  $\rightarrow$  **39**. The observed disaccharides each can be further deprotected selectively at the remaining three positions of the orthogonally protected sugar portion to generate  $4 \times 3 = 12$  monohydroxy disaccharides (e.g., **32** was prepared from **41** by selective deprotection of a 3-*p*-methoxybenzyl group). These structures can then be subjected to the one-pot assembly of tetra- or pentasaccharides, as we have demonstrated here in the synthesis of **57** (Scheme 4b) and is generally illustrated in Scheme 1. Such an approach, with the ultimate aid of the relative reactivity database, forms a basis for the construction of linear and branched oligosaccharide libraries, and approximately 30 fully protected oligosaccharides have been prepared using this reactivity-based one-pot strategy (Table 8). Complete deprotection and selective deprotection of the library will generate a larger library. This work is in progress in our laboratory and will be reported in due course.

## Conclusion

Here we present the results of our first trial study that attempts to bring the practice of oligosaccharide synthesis into a systematic and rapid procedure. To achieve this goal, we pursued an approach based on the chemoselective glycosylation of single acceptors in the presence of other less reactive donors. To bring this concept into predictable and reproducible practice, we have

**Table 8.** Sequences of Protected Oligosaccharides Prepared by Programmed One-Pot Synthesis

Entry	Oligosaccharides	Entry	Oligosaccharides
1	L-Fuc $\alpha$ 1,2Gal $\alpha$ 1,6GlcN	17	Gal $\alpha$ 1,3Gal $\beta$ 1,3GlcN
2	L-Fuc $\beta$ 1,2Gal $\alpha$ 1,6GlcN	18	Gal $\alpha$ 1,3Gal $\beta$ 1,4GlcN
3	L-Fuc $\alpha$ 1,2Gal $\beta$ 1,6GlcN	19	Gal $\alpha$ 1,3Gal $\beta$ 1,4Glc
4	L-Fuc $\alpha$ 1,3Gal $\beta$ 1,3GlcN	20	Gal $\alpha$ 1,3Gal $\beta$ 1,6GlcN
5	L-Fuc $\alpha$ 1,3Gal $\beta$ 1,4GlcN	21	Gal $\alpha$ 1,3Gal $\alpha$ 1,6GlcN
6	L-Fuc $\alpha$ 1,3Gal $\alpha$ 1,4Glc	22	Gal $\alpha$ 1,6Gal $\beta$ 1,3GlcN
7	L-Fuc $\alpha$ 1,3Gal $\beta$ 1,6GlcN	23	Gal $\alpha$ 1,6Gal $\beta$ 1,4GlcN
8	L-Fuc $\beta$ 1,3Gal $\alpha$ 1,6GlcN	24	Gal $\beta$ 1,6Gal $\beta$ 1,4GlcN
9	L-Fuc $\alpha$ 1,4Gal $\beta$ 1,3GlcN	25	Gal $\alpha$ 1,6Gal $\beta$ 1,6GlcN
10	L-Fuc $\alpha$ 1,4Gal $\beta$ 1,4GlcN	26	Gal $\beta$ 1,6Gal $\beta$ 1,6GlcN
11	L-Fuc $\alpha$ 1,4Gal $\alpha$ 1,6GlcN	27	Glc $\alpha$ 1,3Gal $\beta$ 1,6GlcN
12	L-Fuc $\beta$ 1,4Gal $\beta$ 1,6GlcN	28	Glc $\alpha$ 1,3Gal $\beta$ 1,3GlcN
13	L-Fuc $\alpha$ 1,4Gal $\beta$ 1,6GlcN	29	Glc $\alpha$ 1,3Gal $\beta$ 1,4GlcN
		30	GlcN $\beta$ 1,6Gal $\beta$ 1,4Glc
14	L-Fuc $\alpha$ 1,2 Gal $\alpha$ 1,3Gal $\beta$ 1,6GlcN	31	L-Fuc $\alpha$ 1,6 Glc $\alpha$ 1,3Gal $\beta$ 1,4GlcN
15	L-Fuc $\alpha$ 1,4 Gal $\alpha$ 1,3Gal $\beta$ 1,4GlcN		
16	L-Fuc $\alpha$ 1,4GlcN $\beta$ 1,6Gal $\alpha$ 1,4Glc		

developed a general methodology for the easy, rapid, and precise measurement of the relative reactivities of almost any glycosyl donor by HPLC. We employed this methodology to quantify the relative reactivities of a series of glycoside donors for use as off-the-shelf reagents in the one-pot synthesis. In addition to allowing us to plan a series of one-pot sequential syntheses of linear and branched oligosaccharides, this database of donors and reactivities also revealed a wealth of structural factors which contribute to the reactivity of the anomeric position. As observed by others, the electron-withdrawing contribution of same protecting groups about the ring influences reactivity. We also found the identity of the sugar, the position of protecting groups, and other important factors contributing to anomeric reactivity.

During this study, we have demonstrated that, among the monosaccharide and disaccharide structures tested, the fucose core is the most reactive, followed by galactose, glucose, and mannose. For 2-aminoglycosides, we show that their reactivity is significantly influenced by the protecting group at the nitrogen. The  $-NTroc$  group has a large activating effect compared to the  $-NPhth$  or azide group. By utilizing the Troc and Phth groups as a versatile protecting groups for the amine function, we have demonstrated that the change of only a single protection on the amine can be sufficient to regulate the reactivities either of a given monosaccharides or between different monosaccharide structures. The degree of deactivation at the anomeric center by benzoyl protection (as compared to the free hydroxyl at that position) was found to be the greatest at the 4-position on the galactose core, with the overall order of  $4 > 3 > 2 > 6$ .

Because the absolute influence of a given protecting group could not be simply accounted for, we found it necessary to determine the reactivity of each monomer separately. For this purpose, we defined the relative reactivity value (RRV) as a relative measure of reactivity for a given monosaccharide or disaccharide. By measuring the RRVs of up to 50 different mono- and disaccharide structures, we were able to create the first database of donor reactivities and demonstrated its usefulness for rapid one-pot assembly of various oligosaccharide structures. In addition, we observed the linear correlation between the glycosyl donor reactivity and the chemical shift of the anomeric proton by  $^1H$  NMR. To aid in the planning of high-yielding syntheses with available reagents, we report the

first computer program, OptiMer, that searches through the database of characterized donors and identifies sets of monomer donors which are likely to give the best yield. This database can be rapidly expanded to accommodate other mono- and oligosaccharide systems. The further development of this new synthesis strategy will surely impact the rapid access to the molecular diversity of carbohydrate structures to facilitate the discovery of carbohydrate ligands and receptors, which in turn paves a way to a deeper understanding of their biological functions.

## Experimental Section


**General Methods.** Chemicals used were reagent grade and were used as supplied except where noted. Solvents were either dried by standard procedures or used as purchased. Unless otherwise stated, all reactions were performed under an argon atmosphere. All thioglycosides used in this research are *p*-methylphenyl thioglycosides. Compounds **3**,<sup>24a</sup> **4**,<sup>24a</sup> **5**,<sup>24b</sup> **6**,<sup>24b</sup> **7**,<sup>24c</sup> **14**,<sup>24b</sup> **43**,<sup>24a</sup> and **51**<sup>24d</sup> are known structures and were prepared according to the published procedures. All glycosylation experiments were performed by using molecular sieves, which were flame-dried right before the reaction under high vacuum. Analytical thin-layer chromatography was performed using silica gel 60 F<sub>254</sub> glass plates (Merck); compound spots were visualized by UV light (254 nm) and/or by staining with a yellow solution containing Ce(NH<sub>4</sub>)<sub>2</sub>(NO<sub>3</sub>)<sub>6</sub> (0.5 g) and (NH<sub>4</sub>)<sub>6</sub>Mo<sub>7</sub>O<sub>24</sub>·4H<sub>2</sub>O (24.0 g) in 6% H<sub>2</sub>SO<sub>4</sub> (500 mL). Flash column chromatography was performed on silica gel 60 Geduran (35–75  $\mu$ m, EM Science).  $^1H$  NMR spectra were recorded on a Bruker AMX-400 or a Bruker AMX-500 instrument. Low- and high-resolution mass spectra were recorded under fast atom bombardment (FAB) conditions. HPLC measurements were performed on a Hitachi HPLC D-7000 system equipped with UV detector L7400, pump L7100, and software D-7000. All the experiments were performed by using a normal-phase column, 86-100-D5 (Microsorb-MV, Rainin Instrument Co. Inc.) with the solvent system hexanes/EtOAc.

**General Procedure for Competition Experiments.** A mixture of two thioglycoside donors (0.01 mmol of each, **D**<sub>ref</sub> is the reference donor and **D**<sub>x</sub> is any other donor molecule), absolute MeOH (0.05 mmol), and molecular sieves (AW-300) in dichloromethane (1.0 mL) was stirred at room temperature for 10 min. An aliquot of this mixture (30  $\mu$ L) was taken and separately injected (10  $\mu$ L for each injection) into the HPLC in order to determine the baseline separation conditions, and also to measure a coefficient ( $\alpha$ ) between the absorption (*A*) and the concentration of the donor molecule [**D**],  $\alpha = A/[D]$ . A solution of 0.5 M NIS in acetonitrile (20  $\mu$ L, 0.01 mmol) was added to the above mixture, followed by addition of a solution of 0.1 M TfOH (10  $\mu$ L, 0.001 mmol), and the reaction was left at room temperature for 2 h. The mixture was diluted with dichloromethane (2 mL), filtered, washed with saturated aqueous sodium thiosulfate containing 10% sodium hydrogen bicarbonate, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated to dryness. The residue was dissolved in dichloromethane (1.0 mL), and the concentrations of the remaining donors (**D**<sub>x</sub>] and [**D**<sub>ref</sub>]) were measured by HPLC using the same conditions (10  $\mu$ L for each injection) as determined for the mixture before the addition of reagents. An example of such an experiment is given in Figure 3.

**Synthesis of Building Blocks.** Scheme 5 illustrates the representative synthesis of certain building blocks found in Table 1.

**General Procedure for Glycosylation.** To a cold ( $-40$  °C) mixture of glycosyl donor (1.5 equiv), acceptor (1.0 equiv), NIS (1.6 equiv), and MS was added CH<sub>2</sub>Cl<sub>2</sub> by syringe, the mixture was stirred for 20 min, and then TfOH (0.015 equiv) was added. The mixture was stirred at  $-20$  °C for 0.5 h and then gradually raised to room temperature. The reaction was monitored by TLC. After the reaction was finished, solid Na<sub>2</sub>SO<sub>3</sub>, NaHCO<sub>3</sub>, and a few drops of water were added into the reaction mixture, and the mixture was stirred for 5 min, diluted with

(24) (a) Balavoine, G.; Berteina, S.; Gret, A.; Fischer, J.; Lubineau, A. *J. Carbohydr. Chem.* **1995**, *14*, 1217. (b) Magnusson, G. *J. Org. Chem.* **1977**, *42*, 913. (c) Burkart, M. D.; Zhang, Z.; Huang, S.-C.; Wong, C.-H. *J. Am. Chem. Soc.* **1997**, *119*, 11743. (d) DeNinno, M. P.; Etienne, J. B.; Duplantier, K. C. *Tetrahedron Lett.* **1995**, *36*, 669.

Scheme 5. Preparation of Building Blocks<sup>a</sup>

<sup>a</sup> Conditions: (a) NaHCO<sub>3</sub>, MeOH/H<sub>2</sub>O; (b) BzCl, pyridine; (c) NH<sub>2</sub>NH<sub>2</sub>/AcOH; (d) NIS-TfOH, MS, CH<sub>2</sub>Cl<sub>2</sub>; (e) TFA, CH<sub>2</sub>Cl<sub>2</sub>; (f) HF/pyridine, THF; (g) HO(CH<sub>2</sub>)<sub>5</sub>CO<sub>2</sub>Me, BF<sub>3</sub>/OEt<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>; (h) NaOMe, MeOH; (i) *p*-MeOBn(OMe)<sub>2</sub>, CAS, MeCN; (j) NaH, BnBr, DMF; (k) NaCNBH<sub>3</sub>-CF<sub>3</sub>CO<sub>2</sub>H, DMF.

CH<sub>2</sub>Cl<sub>2</sub>, filtered, washed with saturated NaHCO<sub>3</sub> and brine, dried over Na<sub>2</sub>SO<sub>4</sub> (or MgSO<sub>4</sub>), and concentrated. The residue was chromatographed to give the named compounds.

***p*-Methylphenyl 2,3,4,6-Tetra-*O*-acetyl-1-thio- $\alpha$ -D-mannopyranoside (1).** To a mixture of D-mannose pentaacetate (16.0 g, 0.041 mol) and *p*-thiocresol (7.6 g, 0.0615 mol) in CH<sub>2</sub>Cl<sub>2</sub> (200 mL) was added boron trifluoride diethyl etherate (6.8 mL, 0.0533 mol). The mixture was stirred overnight. The reaction mixture was then diluted with CH<sub>2</sub>Cl<sub>2</sub> (200 mL) and washed with saturated NaHCO<sub>3</sub> (2  $\times$  120 mL) and water (100 mL). The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>. The solvent was removed, and the residue was purified by column chromatography on silica gel (hexanes/EtOAc 3:1) to give product (16.2 g, 87%) as a syrup: <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$  7.38 (d, *J* = 8.0 Hz, 2H), 7.12 (d, *J* = 8.0 Hz, 2H), 5.49 (dd, 1H, *J* = 2.5, 1.5 Hz), 5.42 (d, 1H, *J* = 1.0 Hz), 5.30–5.35 (m, 2H), 4.54–4.58 (m, 1H), 4.30 (dd, 1H, *J* = 12.5, 6.0 Hz), 4.11 (dd, 1H, *J* = 12.0, 2.5 Hz), 2.33 (s, 3H), 2.15 (s, 3H), 2.08 (s, 3H), 2.06 (s, 3H), 2.02 (s, 3H); HRMS (M + Cs) calcd for C<sub>21</sub>H<sub>26</sub>O<sub>9</sub>SCs 587.0352, found 587.0331.

***p*-Methylphenyl 2,3,6-Tri-*O*-benzoyl-4-*O*-(2,3,4,6-tetra-*O*-benzoyl- $\beta$ -D-galactopyranosyl)- $\beta$ -D-glucopyranoside (2).** Peracetylated lactoside **6**<sup>24b</sup> (2 g, 2.695 mmol) was dissolved in anhydrous methanol (25 mL), and a solution of 25% NaOMe in methanol (w/v, 0.5 mL) was added dropwise. After being stirred at room temperature for 0.5 h, the solution was neutralized with Amberlite HR-120 (H<sup>+</sup>), filtered, and concentrated. The residue was dissolved in dry pyridine (10 mL) and treated with excess benzoyl chloride (3 mL) and *p*-dimethylamino-pyridine (100 mg) for 5 h at 50 °C. The mixture was evaporated to dryness under reduced pressure, and the residue was diluted with CH<sub>2</sub>Cl<sub>2</sub>

(250 mL), washed with saturated aqueous NaHCO<sub>3</sub> and brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The residue was chromatographed (hexane/EtOAc, 4:1) to give **2** (3.06 g, 96%): [ $\alpha$ ]<sub>D</sub><sup>25</sup> +37.8° (c, 0.5, CHCl<sub>3</sub>); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$  2.23 (s, 3H), 3.69 (d, 2H, *J* = 6.5 Hz), 3.88 (ddd, 1H, *J* = 10.0, 4.5, 1.5 Hz), 3.93 (t, 1H, *J* = 6.5 Hz, H4), 4.18 (t, 1H, *J* = 9.5 Hz), 4.51 (dd, 1H, *J* = 12.0, 5.0 Hz), 4.67 (dd, 1H, *J* = 12.0, 1.5 Hz), 4.85 (d, 1H, *J* = 10.0 Hz), 4.89 (d, *J* = 8.0 Hz), 5.42 (dd, 1H, *J* = 9.5, 1.5 Hz), 5.43 (dd, 1H, *J* = 10.0, 4.5 Hz), 5.74 (dd, 1H, *J* = 10.0, 7.5 Hz), 5.76 (d, 1H, *J* = 3.0 Hz), 5.82 (t, 1H, *J* = 9.5 Hz), 6.90 (d, 2H, *J* = 8.0 Hz), 7.11–7.61 (m, 24H), 7.73 (d, 2H, *J* = 8.0 Hz), 7.9–8.0 (m, 12H); HRMS for C<sub>68</sub>H<sub>56</sub>O<sub>17</sub>SCs (M + Cs) calcd 1309.2293, found 1309.2222.

***p*-Methylphenyl 3,6-Di-*O*-benzoyl-2-deoxy-2-phthalimido-1-thio- $\beta$ -D-glucopyranoside (8).** *p*-Methylphenyl 2-deoxy-2-phthalimido-1-thio- $\beta$ -D-glucopyranoside<sup>24a</sup> (185 mg, 0.44 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (8 mL) was treated with benzoyl chloride (203  $\mu$ L, 1.76 mmol) and pyridine (177  $\mu$ L, 2.2 mmol) (see **2**). The residue was purified by flash chromatography (hexane/EtOAc, 3:1) to give the title compound (205 mg, 75%) as a white solid: [ $\alpha$ ]<sub>D</sub><sup>25</sup> +107° (c, 0.1, CHCl<sub>3</sub>); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  2.02 (s, 3H), 3.70 (s, 1H), 3.86 (t, 1H, *J* = 9.4 Hz), 4.03 (m, 1H), 4.47 (t, 1H, *J* = 10.4 Hz), 4.70 (dd, 1H, *J* = 12.1, 5.1 Hz), 4.78 (dd, 1H, *J* = 12.0, 4.0 Hz), 5.83 (d, 1H, *J* = 10.4 Hz), 5.99 (dd, 1H, *J* = 10.2, 9.1 Hz), 7.23–8.08 (m, 8 H); <sup>13</sup>C NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  21.10, 53.44, 63.71, 70.01, 74.69, 78.21, 83.05, 123.54, 127.30, 128.29, 128.33, 128.63, 129.51, 129.69, 129.78, 129.83, 131.07, 131.43, 133.16, 133.40, 133.59, 134.13, 134.26, 138.29, 166.65, 166.87, 167.14, 167.89; HRMS for C<sub>35</sub>H<sub>29</sub>NO<sub>8</sub>SCs (M + Cs) calcd 756.0668, found 756.0690.



***p*-Methylphenyl 2,3,6-Tri-*O*-Benzoyl-4-*O*-(2,3,4,6-tetra-*O*-benzyl- $\beta$ -*D*-galactopyranosyl)- $\beta$ -*D*-glucopyranoside (9).** The glycosylation of donor **48** (151.2 mg, 0.234 mmol) and the acceptor **10** (100 mg, 0.167 mmol) was performed according to the general procedure described above. Chromatography of the crude material gave the title compound **9** (121 mg, 65%) as white solid and succinimide derivative **58** (22 mg, 15% of the donor **48**) as a byproduct. Data for **9**:  $[\alpha]_D^{25} +26.8^\circ$  (c, 0.5, CHCl<sub>3</sub>); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$  2.25 (s, 3H, Me of STol), 3.38 (m, 2H), 3.76 (dd, 1H, *J* = 10.5, 4.0 Hz), 3.84 (dd, 1H, *J* = 10.5, 2.5 Hz), 3.90–4.0 (m, 3H), 4.17 (t, 1H, *J* = 9.5 Hz), 4.19 (d, 1H, *J* = 11.5 Hz), 4.23 (d, 1H, *J* = 12.0 Hz), 4.28 (d, 1H, *J* = 12.0 Hz), 4.41 (d, 1H, *J* = 11.0 Hz), 4.56 (dd, 1H, *J* = 12.0, 4.5 Hz), 4.59 (d, 2H, *J* = 2.5 Hz), 4.77 (d, 1H, *J* = 11.5 Hz), 4.87 (d, 1H, *J* = 12.0 Hz), 4.94 (dd, 1H, *J* = 12.0, 2.0 Hz), 4.99 (d, 2H, *J* = 3.5 Hz), 5.36 (t, 1H, *J* = 10.0 Hz), 5.85 (t, 1H, *J* = 7.5 Hz), 6.88 (d, 2H, *J* = 8.0 Hz), 7.05–7.52 (m, 35H), 7.63 (t, 1H, *J* = 7.0 Hz), 7.92 (d, 2H, *J* = 8.0 Hz), 7.95 (d, 2H, *J* = 8.0 Hz), 8.02 (d, 2H, *J* = 8.0 Hz); HRMS for C<sub>68</sub>H<sub>64</sub>O<sub>13</sub>SCs (M + Cs) calcd 1253.3122, found 1253.3056. Anal. Calcd for C<sub>68</sub>H<sub>64</sub>O<sub>13</sub>S: C, 72.94; H, 5.75; S, 2.86. Found: C, 72.94; H, 5.60; S, 3.25. Data for **58**: <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$  2.51–2.64 (m, 4H), 3.42 (dd, 1H, *J* = 9.5, 7.0 Hz), 3.49 (dd, 1H, *J* = 9.5, 6.0 Hz), 4.03 (d, 1H, *J* = 2.5 Hz), 4.36–4.49 (m, 5H), 4.55 (dd, 1H, *J* = 10.0, 3.0 Hz), 4.57 (d, 1H, *J* = 9.0 Hz), 4.67 (d, 1H, *J* = 11.5 Hz), 4.75 (d, 1H, *J* = 11.5 Hz), 4.82 (d, 1H, *J* = 11.5 Hz), 4.94 (d, 1H, *J* = 11.5 Hz), 6.13 (d, 1H, *J* = 7.5 Hz), 7.20–7.37 (m, 20H); HRMS for C<sub>38</sub>H<sub>39</sub>O<sub>7</sub>NCs (M + Cs) calcd 754.1781, found 754.1763.

***p*-Methylphenyl 2,3,6-Tri-*O*-benzoyl-1-thio- $\beta$ -*D*-glucopyranoside (10).** The title compound was prepared from peracetylated glucoside **5**<sup>24b</sup> by the following five-step synthesis:

(1) Compound **5** (2.2 g, 4.8 mmol) was treated with 1 M NaOMe in methanol (0.5 mL) in anhydrous methanol (35 mL) by following the procedure described in the preparation of **2**.

(2) The residue was dissolved in dry acetonitrile (20 mL), and *p*-anisaldehyde dimethylacetal (1.3 g, 7 mmol) and camphorsulfonic acid (100 mg) were added. After being stirred at room temperature for 2 h, the mixture was neutralized by addition of pyridine and then evaporated to dryness.

(3) The residue was treated with excess benzoyl chloride (1.64 mL, 13.6 mmol) and 4-dimethylaminopyridine (0.5 g) in dry pyridine (10 mL) for 2 h at 50 °C (see **2**). The residue was crystallized from ethyl acetate and hexane to afford the 2,3-benzoyl-4,6-*p*-methoxybenzylidene product as white crystals (2.4 g, 83% yield for three steps): mp 202–203 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$  2.34 (s, 3H, Me of STol), 3.73 (ddd, 1H, *J* = 14.0, 9.5, 4.5 Hz, H5), 3.75 (s, 3H, OMe), 3.83–3.88 (m, 2H), 4.43 (dd, 1H, *J* = 10.5, 4.5 Hz), 4.96 (d, 1H, *J* = 10.0 Hz, H-1), 5.44 (t, 1H, *J* = 9.5 Hz), 5.49 (s, 1H), 5.77 (t, 1H, *J* = 9.5 Hz), 6.83 (d, 2H, *J* = 9.0 Hz), 7.12 (d, 2H, *J* = 8.0 Hz), 7.25–7.41 (m, 8H), 7.47 (t, 1H, *J* = 7.5 Hz), 7.53 (t, 1H, *J* = 7.5 Hz), 7.93 (d, 2H, *J* = 8.0 Hz), 7.97 (d, 2H, *J* = 8.0 Hz); HRMS for C<sub>35</sub>H<sub>32</sub>O<sub>8</sub>SCs (M + Cs): calcd 745.0872, found 745.0849.

(4) The above-mentioned benzylidene derivative (2.0 g, 3.27 mmol) was suspended in 80% acetic acid/water (v/v, 25 mL), and the reaction was stirred at 50 °C for 1 h. The mixture was evaporated to dryness. The residue was dissolved in dry toluene (20 mL) and evaporated again to dryness. This procedure was repeated three times.

(5) The crude residue was then dissolved in dichloromethane (20 mL), followed by addition of triethylamine (3 mL) and benzoyl chloride (0.57 mL, 4.95 mmol). After 1 h at room temperature, the reaction was quenched by addition of ethyl acetate and water, and the mixture was evaporated to dryness. The product was crystallized from ethyl acetate and hexane to afford **10** (1.5 g, 77%) as white crystals: mp 197 °C;  $[\alpha]_D^{25} +56^\circ$  (c, 0.5, CHCl<sub>3</sub>); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$  2.28 (s, 3H), 3.46 (d, 1H, *J* = 4.0 Hz), 3.84–3.86 (m, 2H), 4.72–4.76 (m, 2H), 4.89 (d, 1H, *J* = 10.0 Hz, H-1), 5.37 (t, 1H, *J* = 9.5 Hz), 5.47 (t, 1H, *J* = 9.0 Hz), 6.96 (d, 2H, *J* = 8.0 Hz), 7.31–7.40 (m, 6H), 7.47–7.54 (m, 4H), 7.63 (t, 1H, *J* = 7.5 Hz), 7.93 (d, 2H, *J* = 8.0 Hz), 7.98 (d, 2H, *J* = 8.0 Hz), 8.09 (d, 2H, *J* = 8.0 Hz); HRMS for C<sub>34</sub>H<sub>30</sub>O<sub>8</sub>SCs (M + Cs) calcd 731.0716, found 731.0689. Anal. Calcd for C<sub>34</sub>H<sub>30</sub>O<sub>8</sub>S: C, 68.21; H, 5.05; S, 5.36. Found: C, 68.79; H, 5.06; S, 5.13.

***p*-Methylphenyl 3,4,6-Tri-*O*-acetyl-2-deoxy-2-phthalimido-1-thio- $\beta$ -*D*-galactopyranoside (11).** 1,3,4,6-Tetra-*O*-acetyl-2-deoxy-2-phthalimido- $\beta$ -*D*-galactopyranose<sup>25</sup> (1.7 g, 3.56 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (20 mL) was treated with thiocresol (663 mg, 5.34 mmol) and BF<sub>3</sub>/Et<sub>2</sub>O (1.5 mL) according to the procedure described in the preparation of **1**. After workup, the crude product was crystallized from Et<sub>2</sub>O to give the title compound **11** (1.62 g, 83%): mp 141–142 °C;  $[\alpha]_D^{25} +45.4^\circ$  (c, 0.5, CHCl<sub>3</sub>); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  1.97 (s, 3H), 2.05 (s, 3H), 2.08 (s, 3H), 2.31 (s, 3H), 4.09–4.24 (m, 3H), 4.62 (t, 1H, *J* = 10.8 Hz), 5.49 (d, 1H, *J* = 3.2 Hz), 5.64 (d, 1H, *J* = 10.8 Hz), 5.80 (dd, 1H, *J* = 10.8, 3.2 Hz), 7.07 (d, 2H, *J* = 8.1 Hz), 7.32 (d, 2H, *J* = 8.1 Hz), 7.76–7.80 (m, 4H); <sup>13</sup>C NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  20.52, 20.69, 21.14, 50.11, 61.63, 66.85, 68.81, 74.48, 84.35, 123.65, 129.62, 133.21, 134.40, 162.01, 163.10, 167.16, 167.90, 171.22; HRMS for C<sub>27</sub>H<sub>27</sub>NO<sub>9</sub>SCs (M + Cs) calcd 674.0461, found 674.0435.

***p*-Methylphenyl 3-*O*-Acetyl-6-*O*-benzoyl-2-deoxy-2-phthalimido-1-thio- $\beta$ -*D*-glucopyranoside (12).** *p*-Methylphenyl 2-deoxy-2-phthalimido-1-thio- $\beta$ -*D*-glucopyranoside<sup>24a</sup> (420 mg, 1.01 mmol) was treated with camphorsulfonic acid (30 mg) and anisaldehyde dimethylacetal (0.2 mL, 1.2 mmol) (see the preparation of **10**). The residue in pyridine (2 mL) was cooled to 0 °C, acetic anhydride (0.3 mL, 3 mmol) was added, and the reaction was stirred for 1.5 h. After workup, the mixture in HOAc/water (1:1, 20 mL) was heated at 60 °C for 30 min. After cooling to room temperature, the reaction mixture was evaporated to dryness. The residue was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (20 mL), washed with saturated aqueous NaHCO<sub>3</sub> and NH<sub>4</sub>Cl, and dried over MgSO<sub>4</sub>, and the solvent was removed under reduced pressure. This material, without further purification, was treated with pyridine (2 mL) and benzoyl chloride (121  $\mu$ L, 1.05 mmol) at 0 °C for 30 min and then evaporated to dryness. The residue was purified by flash chromatography (hexane/EtOAc, 2:1) to give **12** (340 mg, 60% over four steps) as a white white solid:  $[\alpha]_D^{25} -8.6^\circ$  (c, 0.5, CHCl<sub>3</sub>); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  1.88 (s, 3H), 2.24 (s, 3H), 3.51 (m, 1H), 3.71 (t, 1H, *J* = 8.0 Hz), 3.96 (m, 1H), 4.27 (t, 1H, *J* = 10.3 Hz), 4.63–4.75 (m, 2H), 5.76 (m, 1H), 5.80 (d, 1H, *J* = 10.4 Hz), 6.94 (d, 1H, *J* = 8.0 Hz), 7.32 (d, 2H, *J* = 8.1 Hz), 7.60–7.74 (m, 3H), 7.81–7.87 (m, 2H), 8.05–8.08 (?); <sup>13</sup>C NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  20.56, 21.06, 53.54, 63.64, 69.42, 74.07, 77.97, 82.72, 123.53, 127.13, 128.26, 128.33, 129.45, 129.60, 129.72, 129.78, 131.02, 131.46, 133.20, 133.59, 134.20, 134.37, 138.25, 166.67, 167.16, 167.90, 171.22; HRMS for C<sub>30</sub>H<sub>27</sub>NO<sub>8</sub>SCs (M + Cs) calcd 694.0512, found 694.0537.

***p*-Methylphenyl 2,3,4-Tri-*O*-benzoyl-1-thio- $\beta$ -*D*-galactopyranoside (13).** Compound **16** (3.6 g, 5.06 mmol) was treated with the mixture of CH<sub>3</sub>CN–(aq)HF (90:10, 100 mL) for 1 h. The solution was then concentrated and the residue diluted with CH<sub>2</sub>Cl<sub>2</sub> (300 mL), washed with saturated NaHCO<sub>3</sub> (2  $\times$  150 mL), dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated. The residue was purified by flash chromatography (hexane/EtOAc, from 2:1 to 1:2) to give **13** (2.92 g, 96.8%):  $[\alpha]_D^{25} +112.6^\circ$  (c, 1, CHCl<sub>3</sub>); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.01–7.14 (19H), 5.83 (d, 1H, *J* = 3.16 Hz, H-4), 5.77 (t, 1H, *J* = 9.92 Hz, H-2), 5.67 (dd, 1H, *J* = 3.16, 9.88 Hz, H-3), 4.968 (d, 1H, *J* = 9.88 Hz, H-1), 4.08 (t, 1H, *J* = 6.68 Hz, H-5), 3.85 (dd, 1H, *J* = 6.68, 11.88 Hz, H-6), 3.85 (dd, 1H, *J* = 6.68, 11.88 Hz, H-6); <sup>13</sup>C NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  166.47, 165.45, 165.13, 85.73, 77.76, 73.10, 68.91, 67.95, 60.6821.31; HRMS for C<sub>34</sub>H<sub>30</sub>O<sub>8</sub>SCs (M + Cs) calcd 731.0716, found 731.0736.

***p*-Methylphenyl 3,4,6-Tri-*O*-benzoyl-1-thio- $\beta$ -*D*-galactopyranoside (15).** A suspended mixture of *p*-methylphenyl 1-thio- $\beta$ -*D*-galactopyranoside<sup>26</sup> (100 mg, 0.350 mmol) and Bu<sub>2</sub>SnO (266 mg, 1.04 mmol) in toluene/benzene (1:1, 10 mL) was refluxed for 10 min. The mixture was concentrated to a volume of 2 mL by distillation under Ar, and then the hot solution (about 100 °C) was treated with benzoyl chloride (130  $\mu$ L, 1.12 mmol). After being stirred for 1 h at this temperature, the reaction mixture was diluted with EtOAc (20 mL), cooled to room temperature, filtered through Celite, and concentrated. Chromatography of the residue (hexane/EtOAc, 4:1 to 2:1 to 1:1) furnished **15** (192 mg, 91.7%) as a white solid:  $[\alpha]_D^{25} +15^\circ$  (c, 0.5, CHCl<sub>3</sub>); <sup>1</sup>H NMR

(25) Nilsson, U.; Ray, R. K.; Magnusson, G. *Carbohydr. Res.* **1990**, *208*, 260.

(26) Vargas-Berenguel, A.; Meldal, M.; Paulsen, H.; Jensen, K. J.; Bock, K. *J. Chem. Soc., Perkin Trans. 1* **1994**, 3287.

(250 MHz, CDCl<sub>3</sub>)  $\delta$  5.91 (d, 1H,  $J$  = 3.1 Hz, H-4), 5.43 (dd, 1H,  $J$  = 3.3, 9.7 Hz, H-3), 4.720 (d, 1H,  $J$  = 9.6 Hz, H-1), 4.29 (bt, 1H,  $J$  = 6.5 Hz, H-5), 4.62 (dd, 1H,  $J$  = 6.6 Hz, H-6), 4.37 (dd, 1H,  $J$  = 5.4, 11.5 Hz, H-6'), 4.03 (t, 1H,  $J$  = 9.6, 11.5 Hz, H-2), 2.38 (s, 3H, Me); <sup>13</sup>C NMR (270 MHz, CDCl<sub>3</sub>)  $\delta$  165.98, 165.90, 165.29, 88.26, 74.97, 74.47, 68.59, 67.34, 62.45, 21.28; HRMS for C<sub>40</sub>H<sub>44</sub>O<sub>8</sub>SiCs (M + Cs) calcd 845.1581, found 845.1609.

***p*-Methylphenyl 2,3,4-Tri-*O*-benzoyl-6-*O*-*tert*-butyldimethylsilyl-1-thio- $\beta$ -D-galactopyranoside (16).** A solution of *p*-methylphenyl 1-thio- $\beta$ -D-galactopyranoside<sup>26</sup> (4.0 g, 14.0 mmol) in DMF (10 mL) was treated with imidazole (1.4 g, 20.6 mmol) and *tert*-butyldimethylsilyl chloride (2.26 g, 14.5 mmol) at 0 °C for 12 h. The mixture was evaporated under reduced pressure, and the residue was purified by flash chromatography (hexane/EtOAc, from 4:1 to 1:1) to give the corresponding 6-*O*-*tert*-butyldimethylsilyl ether (5.3 g, 96%) as a syrup. Part of this product (4.0 g, 10.0 mmol) was treated with pyridine (50 mL), an excess of benzoyl chloride (8 mL), and 4-dimethylamino-pyridine (100 mg) at 50 °C for 1 h. After workup, the residue was purified by chromatography on a silica gel column (hexane/EtOAc, 4:1) to afford the title compound **16** (6.96 g 97.7%) as a syrup: [ $\alpha$ ]<sub>D</sub><sup>25</sup> +102° (c, 0.8, CHCl<sub>3</sub>); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  5.93 (d, 1H,  $J$  = 3.2, H-4), 5.66 (t, 1H,  $J$  = 9.84 Hz, H-2), 5.56 (dd, 1H,  $J$  = 3.24, 9.96 Hz, H-3), 4.935 (d, 1H,  $J$  = 9.80 Hz, H-1), 4.05 (bt, 1H,  $J$  = 7.08 Hz, H-5), 3.85 (dd, 1H,  $J$  = 5.92, 10.0 Hz, H-6), 3.85 (dd, 1H,  $J$  = 7.52, 10.0 Hz, H-6); <sup>13</sup>C NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  165.52, 165.21, 165.09, 86.09, 73.32, 68.12, 67.95, 60.96, 25.77, 25.73, 21.34, -5.60, -5.70; HRMS for C<sub>40</sub>H<sub>44</sub>O<sub>8</sub>SiCs (M + Cs) calcd 845.1581, found 845.1609.

***p*-Methylphenyl 4,6-*O*-Benzylidene-2-deoxy-2-phthalimido-1-thio- $\beta$ -D-glucopyranoside (17).** *p*-Methylphenyl 2-deoxy-2-phthalimido-1-thio- $\beta$ -D-glucopyranoside<sup>24a</sup> (820 mg, 1.98 mmol) was treated with benzaldehyde dimethylacetate (385  $\mu$ L, 2.56 mmol) and camphorsulfonic acid (50 mg) in dry CH<sub>3</sub>CN (20 mL) according to the procedure described for the preparation of **10**. The residue was crystallized from EtOH (-25 °C) to give **17** (780 mg, 79%) as white crystals: mp 121–122 °C; [ $\alpha$ ]<sub>D</sub><sup>25</sup> +34° (c, 0.5, CHCl<sub>3</sub>); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.75–7.06 (13H), 5.624 (d, 1H,  $J$  = 10.52 Hz, H-1), 5.60 (dd, 1H,  $J$  = 2.96, 9.48 Hz, H-3), 4.39 (dd, 1H,  $J$  = 4.76, 10.48 Hz, H-6), 4.30 (t, 1H,  $J$  = 10.16 Hz, H-2), 3.81 (t, 1H,  $J$  = 10.16 Hz, H-6), 3.67 (dd, 1H,  $J$  = 4.88, 9.80 Hz, H-5), 3.58 (t, 1H,  $J$  = 9.16 Hz, H-4), 2.29 (s, 3H, Me); <sup>13</sup>C NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  101.93, 84.43, 81.88, 70.24, 69.71, 68.55, 55.57, 21.12; HRMS for C<sub>28</sub>H<sub>25</sub>NO<sub>6</sub>SCs (M + Cs) calcd 636.0457, found 636.0475.

***p*-Methylphenyl 2-Azido-4,6-*O*-benzylidene-3-*O*-chloroacetyl-2-deoxy-1-thio- $\beta$ -D-galactopyranoside (18).** The title compound was prepared from *p*-methylphenyl 2-dexoy-2-azido-1-thio- $\beta$ -D-galactopyranoside<sup>27</sup> (527 mg, 1.70 mmol), benzaldehyde dimethylacetate (280  $\mu$ L, 1.87 mmol), and camphorsulfonic acid (30 mg, 0.15 mmol) in dry CH<sub>3</sub>CN (15 mL) as described above. Flash chromatography of the crude residue (hexane/EtOAc, 2:1) gave the corresponding 4,6-*O*-benzylidene derivative **18a** (584 mg, 86%) as a white solid: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  2.34 (s, 3H), 3.39 (s, 1H), 3.49 (t, 1H,  $J$  = 7.6 Hz), 3.57 (m, 1H), 3.94 (dd, 1H,  $J$  = 10.0, 1.2 Hz), 4.05 (d, 1H,  $J$  = 3.5 Hz), 4.31 (d, 1H,  $J$  = 9.5 Hz), 4.32 (m, 1H), 7.32 (d, 2H,  $J$  = 8.1 Hz), 7.60–7.74 (m, 5H), 7.81–7.87 (m, 2H); <sup>13</sup>C NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  21.10, 61.70, 69.0, 69.5, 72.8, 79.2, 84.8, 101.1, 126.2, 126.5, 128.1, 129.2, 129.6, 134.5, 137.3, 138.5; HRMS for C<sub>20</sub>H<sub>21</sub>N<sub>3</sub>O<sub>4</sub>SNa (M + Na) calcd 422.1150, found 422.1134.

The above-mentioned 4,6-*O*-benzylidene derivative (212 mg, 0.53 mmol) was dissolved in dry pyridine (5 mL) and cooled to 0 °C. The mixture was treated with chloroacetyl chloride (47.8  $\mu$ L, 0.6 mmol), and the reaction progress was monitored by TLC. After the mixture was stirred for 20 min at room temperature, the solvent was removed by evaporation under a high vacuum, and the residue was purified on a silica gel column (hexane/EtOAc, 2:1) to afford **18** (247 mg, 98%) as a white solid: [ $\alpha$ ]<sub>D</sub><sup>25</sup> -28° (c, 0.5, CHCl<sub>3</sub>); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  2.34 (s, 3H), 3.56 (m, 1H), 3.81 (t, 1H,  $J$  = 10.1 Hz), 4.00 (dd, 1H,  $J$  = 12.4, 1.6 Hz), 4.08 (AB<sub>q</sub>, 2H,  $J$  = 12.2 Hz), 4.36 (dd,

1H,  $J$  = 3.4, 0.8 Hz), 4.39 (dd, 1H,  $J$  = 12.4, 1.7 Hz), 4.45 (d, 1H,  $J$  = 9.8 Hz), 4.84 (dd, 1H,  $J$  = 10.8, 3.4 Hz), 5.47 (s, 1H), 7.05–7.07 (m, 2H), 7.37–7.40 (m, 5H), 7.60–7.62 (m, 2H); <sup>13</sup>C NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  21.25, 40.45, 58.08, 69.11, 69.38, 72.27, 76.68, 85.21, 100.92, 125.77, 126.42, 128.16, 129.28, 129.58, 134.72, 137.32, 138.35, 166.83; HRMS for C<sub>22</sub>H<sub>22</sub>N<sub>3</sub>O<sub>5</sub>SClNa (M + Na) calcd 498.0866, found 498.0882.

***p*-Methylphenyl 2,4,6-Tri-*O*-benzoyl-1-thio- $\beta$ -D-galactopyranoside (19).** Compound **13** (300 mg, 0.502 mmol) was dissolved in the mixture of pyridine/H<sub>2</sub>O (4:1, 3 mL) to which AgF (30 mg) was added, and the mixture was stirred at 50 °C for 20 min. The reaction mixture was concentrated under reduced pressure and the residue was chromatographed (hexane/EtOAc, 2:1) to give **19** (96 mg, 32%) as white powder: [ $\alpha$ ]<sub>D</sub><sup>25</sup> -10.4° (c, 0.5, CHCl<sub>3</sub>); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.11–7.02 (19H), 5.77 (d, 1H,  $J$  = 3.36 Hz, H-4), 5.26 (t, 1H,  $J$  = 9.64 Hz, H-2), 4.879 (d, 1H,  $J$  = 9.88 Hz, H-1), 4.58 (dd, 1H,  $J$  = 7.24, 11.56 Hz, H-6), 4.45 (dd, 1H,  $J$  = 5.44, 11.60 Hz, H-6), 3.85 (bt, 1H,  $J$  = 6.44 Hz, H-5), 4.15 (dq, 1H,  $J$  = 3.56, 6.28, 9.64 Hz, H-3), 2.77 (d, 1H,  $J$  = 6.24 Hz, OH), 2.34 (s, 3H, Me); HRMS for C<sub>34</sub>H<sub>30</sub>O<sub>8</sub>SCs (M + Cs) calcd 731.0716, found 731.0737. Anal. Calcd for C<sub>34</sub>H<sub>30</sub>O<sub>8</sub>S: C, 68.21; H, 5.05; S, 5.36. Found: C, 67.65; H, 4.96; S, 5.45.

***p*-Methylphenyl 4,6-*O*-Benzylidene-2,3-di-*O*-chloroacetyl-1-thio- $\beta$ -D-galactopyranoside (20).** *p*-Methylphenyl 1-thio- $\beta$ -D-galactopyranoside<sup>26</sup> (3.5 g, 12.24 mmol) was suspended in CH<sub>3</sub>CN (30 mL) and treated with benzaldehyde dimethylacetate (9.35 mL, 18.36 mmol) and camphorsulfonic acid (100 mg). The mixture was stirred at room temperature until all the starting material had been consumed (2 h). After evaporation of the solvent, the crude product was crystallized from MeOH to afford the corresponding 4,6-*O*-benzylidene derivative (3.8 g, 83%). Part of this product (200 mg, 0.535 mmol) was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (5 mL) and treated with pyridine (300  $\mu$ L) and chloroacetyl chloride (153  $\mu$ L, 1.91 mmol). After usual workup, the crude product was purified by chromatography (hexane/EtAc, 1:1) to give the title compound **20** (276 mg, 98%) as a white solid: [ $\alpha$ ]<sub>D</sub><sup>25</sup> -1° (c, 0.5, CHCl<sub>3</sub>); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$  7.49 (d, 2H,  $J$  = 8.0 Hz), 7.09 (d, 2H,  $J$  = 8.0 Hz), 5.45 (s, 1H), 5.24 (t, 1H,  $J$  = 10.0 Hz), 5.08 (dd, 1H,  $J$  = 3.5, 12.4 Hz), 4.68 (d, 1H,  $J$  = 10.0 Hz), 4.4 (m, 2H), 4.11–4.01 (m, 6H), 3.62 (s, 1H), 2.35 (s, 3H); HRMS for C<sub>24</sub>H<sub>24</sub>Cl<sub>2</sub>O<sub>7</sub>SCs (M + Cs) calcd 658.9674, found 658.9692.

***p*-Methylphenyl 3,4,6-Tri-*O*-acetyl-2-deoxy-2-(2,2,2-trichloroethoxycarbonylamino)-1-thio- $\beta$ -D-glucopyranoside (21).** The title compound was prepared from 1,3,4,6-tetra-*O*-acetyl-2-deoxy-2-(2,2,2-trichloroethoxycarbonylamino)- $\beta$ -D-glucopyranose<sup>28</sup> (11.8 g, 22.5 mmol), thiocresol (3.07 g, 24.75 mmol), and BF<sub>3</sub>/Et<sub>2</sub>O (10 mL) in dry CH<sub>2</sub>Cl<sub>2</sub> (60 mL) by following the procedure described above (see **1**). The crude product was crystallized from ether to give **21** (11.8 g, 89%) as white crystals: mp 175–176 °C; [ $\alpha$ ]<sub>D</sub><sup>25</sup> +3° (c, 0.5, CHCl<sub>3</sub>); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  2.00 (s, 3H), 2.01 (s, 3H), 2.09 (s, 3H), 2.35 (s, 3H), 3.71–3.73 (m, 1H), 4.11–4.25 (m, 2H), 4.73 (d, 1H,  $J$  = 12.0 Hz), 4.79 (d, 1H,  $J$  = 10.8 Hz), 5.01 (t, 1H,  $J$  = 9.8 Hz), 5.26 (d, 1H,  $J$  = 9.8 Hz), 5.31 (d, 1H,  $J$  = 9.1 Hz), 7.11 (d, 2H,  $J$  = 8.0 Hz), 7.41 (d, 2H,  $J$  = 8.0 Hz); <sup>13</sup>C NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  20.56, 20.61, 20.73, 21.15, 54.93, 62.25, 68.44, 73.14, 74.47, 75.70, 86.65, 95.36, 127.84, 129.71, 133.62, 138.70, 153.85, 169.45, 170.61; HRMS for C<sub>22</sub>H<sub>26</sub>NO<sub>6</sub>SCl<sub>3</sub>Na (M + Na) calcd 610.0266, found 610.0286. Anal. Calcd for C<sub>22</sub>H<sub>26</sub>NO<sub>6</sub>SCl<sub>3</sub>: C, 45.03; H, 4.47; N, 2.39. Found: C, 45.46; H, 4.26; N, 2.30.

***p*-Methylphenyl 2,3,6-Tri-*O*-benzoyl-1-thio- $\beta$ -D-galactopyranoside (22).** Compound **33** (200 mg, 0.342 mmol) was dissolved in a mixture of TFA/CH<sub>2</sub>Cl<sub>2</sub> (1:1, 5 mL) and stirred for 1 h. The reaction mixture was diluted with CH<sub>2</sub>Cl<sub>2</sub> (50 mL), washed with saturated NaHCO<sub>3</sub>, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The residue was further treated with BzCl (56  $\mu$ L, 0.479 mmol) and pyridine. After general workup, the residue was chromatographed (hexanes/AcOEt, 3:2) to give **22** (153 mg, 85%): <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$  8.16–6.95 (19H), 5.80 (t, 1H,  $J$  = 10.0 Hz, H-2), 5.38 (dd, 1H,  $J$  = 3.0, 10.0 Hz, H-3), 4.920 (d, 1H,  $J$  = 10.0 Hz, H-1), 4.66 (m, 2H, H-6), 4.40 (d, 1H,  $J$  =

(27) Luening, B.; Norberg, T.; Tejbrant, J. *Glycoconjugate J.* **1989**, *6*, 5–19.

(28) Boullanger, P.; Jouineau, M.; Bouammal, B.; Lafont, D.; Descotes, G. *Carbohydr. Res.* **1990**, *202*, 151.



2.50 Hz, H-4), 4.12 (bt, 1H,  $J = 6.0$  Hz, H-5), 2.27 (s, 3H, -Me);  $^{13}\text{C}$  NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$  166.4, 165.8, 165.3, 87.1, 76.2, 67.9, 67.6, 63.4, 21.1; HRMS (M + Cs) calcd for  $\text{C}_{34}\text{H}_{30}\text{O}_8\text{SCs}$  731.0716, found 731.0736.

***p*-Methylphenyl 4,6-*O*-Benzylidene-2-deoxy-2-phthalimido-1-thio- $\beta$ -D-galactopyranoside (23a).** *p*-Methylphenyl 2-deoxy-2-phthalimido-1-thio- $\beta$ -D-galactopyranoside (1.5 g, 3.91 mmol) in dry  $\text{CH}_2\text{Cl}_2$  (15 mL) was treated with camphorsulfonic acid (30 mg, 0.15 mmol) and benzaldehyde dimethylacetal (0.59 mL, 3.94 mmol). Flash chromatography (hexane/AcOEt, 1:2) of the residue gave **23a** (1.83 g, 93%) as a white solid:  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$  2.35 (s, 3H), 3.70 (m, 1H), 4.06 (dd, 1H,  $J = 12.0, 2.0$  Hz), 4.12 (dd, 1H,  $J = 14.5, 7.0$  Hz), 4.28 (m, 1H), 4.39–4.51 (m, 3H), 5.56 (s, 1H), 5.61 (d, 1H,  $J = 10$  Hz, H-1), 7.07 (d, 2H,  $J = 8.0$  Hz), 7.39–7.48 (m, 7H), 7.72–7.87 (m, 4H); HRMS (M + Cs) calcd for  $\text{C}_{28}\text{H}_{25}\text{O}_6\text{NSCs}$  636.0457, found 636.0435.

***p*-Methylphenyl 4,6-*O*-Benzylidene-3-*O*-chloroacetyl-2-deoxy-2-N-phthalimido-1-thio- $\beta$ -D-galactopyranoside (23).** Compound **23a** (580 mg, 1.15 mmol) was treated with chloroacetyl chloride (238  $\mu\text{L}$ , 3.45 mmol) and pyridine (5 mL) at 0 °C according to the procedure described above (see the preparation of **18**). The residue was purified by flash chromatography (hexane/EtOAc, 2:1) to give **23** (647 mg 97%) as a white solid:  $[\alpha]_D^{25} + 10^\circ$  (c, 0.5,  $\text{CHCl}_3$ );  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$  2.34 (s, 3H), 3.75 (s, 1H), 3.82–3.90 (AB<sub>q</sub>, 2H,  $J = 15$  Hz), 4.07 (dd, 1H,  $J = 11.5, 1.5$  Hz), 4.40 (dd, 1H,  $J = 12.5, 1.5$  Hz), 4.51 (d, 1H,  $J = 3.5$  Hz), 4.77 (t, 1H,  $J = 10.5$ ), 5.52 (s, 1H), 5.67 (d, 1H,  $J = 10.4$  Hz), 5.76–5.79 (dd, 1H,  $J = 11.0, 3.5$  Hz), 7.04 (d, 2H,  $J = 8.0$  Hz), 7.38–7.46 (m, 7H), 7.74–7.77 (m, 2H), 7.84–7.89 (m, 2H);  $^{13}\text{C}$  NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$  21.22, 40.47, 49.33, 69.63, 71.74, 72.57, 82.50, 101.03, 123.49, 123.68, 126.53, 126.57, 126.72, 128.15, 129.18, 129.53, 131.27, 131.46, 134.15, 134.28, 134.32, 137.41, 138.40, 166.79, 166.87, 168.30; HRMS (M + Cs) calcd for  $\text{C}_{30}\text{H}_{26}\text{NO}_7\text{SiCs}$  712.0173, found 712.0196.

***p*-Methylphenyl 2-*O*-Benzoyl-4,6-*O*-benzylidene-3-*O*-chloroacetyl-1-thio- $\beta$ -D-galactopyranoside (24).** Compound **42** (80 mg, 0.167 mmol) was treated with  $\text{ClAcCl}$  (27  $\mu\text{L}$ , 0.335 mmol) and pyridine (100  $\mu\text{L}$ ) in  $\text{CH}_2\text{Cl}_2$  (2 mL). Chromatography (hexanes/AcOEt, 1:1) of the residue gave **24** (87 mg, 94%) as a white powder:  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$  8.05–7.04 (14H), 5.54 (t, 1H,  $J = 10.0$  Hz, H-2), 5.49 (s, 1H, ArCH), 5.22 (dd, 1H,  $J = 3.5, 10.0$  Hz, H-3), 4.828 (d, 1H,  $J = 10.0$  Hz, H-1), 4.45 (d, 1H,  $J = 3.5$  Hz, H-4), 4.43 (d, 1H,  $J = 11.0$  Hz, H-6), 4.06 (d, 1H,  $J = 11.0$  Hz, H-6), 3.98 and 3.89 (d<sub>AB</sub>, 1H each,  $J = 15.0$  Hz,  $\text{ClCH}_2$ ), 3.67 (bs, 1H, H-5), 2.34 (s, 3H, Me);  $^{13}\text{C}$  NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$  167.2, 164.8, 101.2, 85.2, 75.0, 73.3, 69.6, 69.1, 67.2, 40.6, 21.05; HRMS (M + Cs) calcd for  $\text{C}_{29}\text{H}_{27}\text{O}_7\text{-ClCs}$  687.0220, found 687.0235.

***p*-Methylphenyl 2-*O*-Benzoyl-6-*O*-tert-butylidiphenylsilyl-4-*O*-levulinyl-1-thio- $\beta$ -D-galactopyranoside (25).** To a stirred solution of **35** (1.1 g, 1.3 mmol) in  $\text{CH}_2\text{Cl}_2$  (45 mL) was added trifluoroacetic acid (8 mL) at –20 °C. After the solution was stirred for 20 min at this temperature, methanol (8 mL) and  $\text{CH}_2\text{Cl}_2$  (80 mL) were then added to the reaction mixture, and the mixture was washed with saturated  $\text{NaHCO}_3$  (3  $\times$  30 mL) and brine (30 mL) and then dried over  $\text{Na}_2\text{SO}_4$ . After removal of the solvent, the residue was purified by chromatography on a silica gel column (hexanes/EtOAc, 2.5:1) to yield **25** (547 mg, 58%) as white solids:  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$  8.08 (d,  $J = 7.5$  Hz, 2H), 7.66 (t,  $J = 7.5$  Hz, 4H), 7.59 (t, 1H,  $J = 7.5$  Hz), 7.37–7.48 (m, 8H), 7.33 (d, 2H,  $J = 8.0$  Hz), 7.02 (d, 2H,  $J = 8.5$  Hz), 5.58 (d, 1H,  $J = 3.5$  Hz), 5.13 (t, 1H,  $J = 10.0$  Hz), 4.76 (d, 1H,  $J = 10.0$  Hz), 3.95 (dt, 1H,  $J = 3.0, 8.5$  Hz), 3.76–3.82 (m, 2H), 3.66–3.72 (m, 1H), 3.01 (d, 1H,  $J = 8.0$  Hz), 2.67–2.79 (m, 2H), 2.42–2.56 (m, 2H), 2.30 (s, 3H), 2.16 (s, 3H), 1.05 (s, 9H);  $^{13}\text{C}$  NMR (125 MHz,  $\text{CDCl}_3$ )  $\delta$  207.7, 172.0, 166.3, 138.1, 135.6, 135.6, 133.2, 133.1, 133.1, 133.0, 130.0, 129.8, 129.7, 129.6, 128.9, 128.4, 127.7, 86.7, 77.83, 73.18, 71.58, 70.36, 61.97, 38.41, 29.68, 28.17, 26.75, 21.13, 19.11; HRMS (M + Cs) calcd for  $\text{C}_{41}\text{H}_{46}\text{O}_8\text{SiCs}$  859.1737, found 859.1704. Anal. Calcd for  $\text{C}_{41}\text{H}_{46}\text{O}_8\text{SiCs}$ : C, 67.74; H, 6.38; S, 4.41. Found: C, 68.10; H, 6.46; S, 4.91.

***p*-Methylphenyl 2-*O*-Benzoyl-3-*O*-(2,3,4,6-tetra-*O*-benzyl- $\alpha$ -D-glucopyranosyl)-6-*O*-tert-butylidiphenylsilyl-4-*O*-levulinyl-1-thio- $\beta$ -D-galactopyranoside (26).** Compound **26** was prepared from **25** (60.0

mg) and **43** (80.1 mg) as described in the general glycosylation procedure to yield 93.1 mg (90%):  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$  7.98 (dd,  $J = 8.0, 1.0$  Hz, 2H), 7.63–7.69 (m, 4H), 7.16–7.45 (m, 29H), 7.00 (d, 2H,  $J = 8.0$  Hz), 6.79 (dd, 2H,  $J = 8.0, 2.0$  Hz), 5.66 (d, 1H,  $J = 3.0$  Hz), 5.46 (t, 1H,  $J = 9.0$  Hz), 5.16 (d, 1H,  $J = 3.5$  Hz), 4.81 (d, 1H,  $J = 11.0$  Hz), 4.69 (d, 1H,  $J = 12.0$  Hz), 4.59 (d, 2H,  $J = 11.0$  Hz), 4.54 (d, 1H,  $J = 11.5$  Hz), 4.46 (d, 1H,  $J = 12.0$  Hz), 4.36 (d, 1H,  $J = 12.0$  Hz), 4.20 (d, 1H,  $J = 11.0$  Hz), 4.05–4.07 (m, 1H), 3.80 (dd, 1H,  $J = 9.5, 6.0$  Hz), 3.72 (t, 1H,  $J = 6.0$  Hz), 3.63–3.69 (m, 4H), 3.39–3.44 (m, 2H), 3.35 (t, 1H,  $J = 9.5$  Hz), 3.30 (dd, 1H,  $J = 10.5, 4.0$  Hz), 2.39–2.45 (m, 1H), 2.23–2.33 (m, 6H), 1.95 (s, 3H), 1.06 (s, 9H);  $^{13}\text{C}$  NMR (125 MHz,  $\text{CDCl}_3$ )  $\delta$  206.1, 171.6, 165.0, 138.6, 138.5, 138.4, 137.9, 137.9, 135.6, 135.6, 133.1, 133.0, 132.9, 129.8, 129.7, 129.7, 129.6, 129.5, 129.1, 128.6, 128.3, 128.2, 128.2, 127.9, 127.8, 127.7, 127.7, 127.6, 127.5, 127.4, 127.3, 127.3, 127.1, 93.32, 87.08, 81.41, 79.31, 77.96, 77.38, 75.45, 74.28, 73.91, 73.31, 73.17, 70.54, 68.26, 65.31, 62.22, 37.84, 29.66, 29.50, 27.98, 26.76, 21.09, 19.13; HRMS (M + Cs) calcd for  $\text{C}_{75}\text{H}_{80}\text{O}_{13}\text{SiCs}$  1381.4143, found 1381.4077.

***p*-Methylphenyl 3,6-Di-*O*-benzoyl-2-deoxy-2-(2,2,2-trichloroethoxycarbonylamino)-1-thio- $\beta$ -D-glucopyranoside (27).** Compound **21** (2.0 g, 3.41 mmol) in MeOH (10 mL) was treated with a catalytic amount of 1 M NaOMe for 5 h, and the solution was then neutralized with IR-120 ( $\text{H}^+$ ), filtered, and concentrated. To a solution of the crude product (610 mg, 1.324 mmol), pyridine (700  $\mu\text{L}$ ), and DMAP (50 mg) in  $\text{CH}_2\text{Cl}_2$  (20 mL) was added  $\text{BzCl}$  (338  $\mu\text{L}$ , 2.916 mmol). The mixture was refluxed for 5 h under Ar and then concentrated and coevaporated twice with toluene, diluted with  $\text{CH}_2\text{Cl}_2$  (100 mL), washed with 10% aqueous  $\text{H}_2\text{SO}_4$ , brine, and saturated aqueous  $\text{NaHCO}_3$ , dried over  $\text{Na}_2\text{SO}_4$ , filtered, and concentrated. Column chromatography (hexane/AcOEt, 2:1 to 1:2) of the residue gave **27** (495 mg, 56%) as a white solid:  $[\alpha]_D^{25} + 28.4^\circ$  (c, 0.5,  $\text{CHCl}_3$ );  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$  5.50 (d, 1H,  $J = 9.5$  Hz, H-2), 5.41 (t, 1H,  $J = 9.5$  Hz, H-3), 4.844 (d, 1H,  $J = 10.0$  Hz, H-1), 4.74–4.64 (m, 3H), 4.55 (d, 1H,  $J = 12.0$  Hz,  $\text{OCH}_2\text{CCl}_3$ ), 3.90 (q, 1H,  $J = 10.0$  Hz, H-2), 3.79 (m, 2H, H-5, H-4), 3.42 (d, 1H,  $J = 5.0$  Hz, OH), 2.27 (s, 3H, Me); HRMS (M + Cs) calcd for  $\text{C}_{30}\text{H}_{28}\text{O}_8\text{Cl}_3\text{NSCs}$  799.9655, found 799.9680.

***p*-Methylphenyl 2-*O*-Benzoyl-3-*O*-(2,3,4,6-tetra-*O*-benzyl- $\alpha$ -D-glucopyranosyl)-4-*O*-levulinyl-1-thio- $\beta$ -D-galactopyranoside (28).** Compound **28** was prepared from **26** (76.0 mg) as described for the preparation of **36**, yielding 48.3 mg (79%):  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.99 (d,  $J = 7.5$  Hz, 2H), 7.43 (t,  $J = 7.4$  Hz, 1H), 7.36 (d,  $J = 8.0$  Hz, 2H), 7.20–7.31 (m, 20H), 7.09 (d,  $J = 8.1$  Hz, 2H), 6.84 (dd,  $J = 7.5, 2.0$  Hz, 2H), 5.48–5.52 (m, 2H), 4.98 (d,  $J = 3.4$  Hz, 1H), 4.84 (d,  $J = 10.9$  Hz, 1H), 4.74 (d,  $J = 9.9$  Hz, 1H), 4.66 (d,  $J = 10.9$  Hz, 1H), 4.61 (s, 2H), 4.58 (d,  $J = 11.4$  Hz, 1H), 4.42 (d,  $J = 12.0$  Hz, 1H), 4.27 (d,  $J = 12.0$  Hz, 1H), 4.22 (d,  $J = 11.3$  Hz, 1H), 4.04–4.08 (m, 1H), 3.68–3.79 (m, 3H), 3.57–3.63 (m, 2H), 3.38–3.44 (m, 2H), 3.15–3.23 (m, 2H), 2.64 (bs, 1H), 2.26–2.53 (m, 7H), 2.09 (s, 3H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  206.73, 173.55, 165.07, 138.58, 138.44, 138.40, 138.23, 137.77, 133.13, 133.08, 129.77, 129.56, 128.73, 128.29, 128.25, 127.96, 127.80, 127.71, 127.60, 127.51, 127.43, 127.24, 127.14, 94.32, 87.00, 81.46, 78.96, 77.28, 75.44, 74.76, 74.24, 73.31, 73.15, 70.66, 69.04, 69.03, 67.90, 66.20, 60.21, 37.72, 29.63, 27.82, 21.11; HRMS (M + Cs) calcd for  $\text{C}_{59}\text{H}_{62}\text{O}_{13}\text{SCs}$  1143.2965, found 1143.2920.

***p*-Methylphenyl 2-*O*-Benzyl-4,6-*O*-benzylidene-3-*O*-chloroacetyl-1-thio- $\beta$ -D-galactopyranoside (29).** Compound **49** (200 mg, 0.431 mmol) was treated with chloroacetyl chloride (69  $\mu\text{L}$ , 0.862 mmol) and pyridine (2.0 mL). The residue was purified by chromatography (hexanes/AcOEt, 1:1) to give **29** (229 mg, 98%) as a syrup:  $[\alpha]_D^{25} + 27.4^\circ$  (c, 0.5,  $\text{CHCl}_3$ );  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.63–7.04 (14H), 5.48 (s, 1H, ArCH), 5.01 (dd, 1H,  $J = 3.36, 9.64$  Hz, H-3), 4.81 and 4.50 (d, 1H each,  $J = 10.96$  Hz, ArCH<sub>2</sub>), 4.642 (d, 1H,  $J = 9.5$  Hz, H-1), 4.40 (dd, 1H,  $J = 1.5, 12.5$  Hz, H-6), 4.39–4.36 (m, 2H), 4.00–3.79 (m, 4H), 3.50 (bs, 1H, H-5), 2.36 (d, 1H,  $J = 11.0$  Hz, OH), 2.35 (s, 3H, Me);  $^{13}\text{C}$  NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$  166.78, 100.75, 86.35, 77.03, 75.11, 73.60, 73.31, 69.07, 68.96, 40.50, 21.02; HRMS (M + Cs) calcd for  $\text{C}_{29}\text{H}_{29}\text{O}_6\text{ClSCs}$  673.0428, found 673.0457. Anal. Calcd for  $\text{C}_{29}\text{H}_{29}\text{O}_6\text{ClSCs}$ : C, 64.38; H, 5.40. Found: C, 64.18; H, 5.32.



***p*-Methylphenyl 2-*O*-Benzoyl-6-*O*-(2,3,4,6-tetra-*O*-benzyl- $\beta$ -D-galactopyranosyl)-4-*O*-levulinyl-3-*O*-*p*-methoxybenzyl-1-thio- $\beta$ -D-galactopyranoside (30).** Compound **30** was prepared from **36** (49.0 mg) and **48** (78.1 mg) as described in the general glycosylation procedure (16.2 mg, 18%):  $^1\text{H NMR}$  (500 MHz,  $\text{CDCl}_3$ )  $\delta$  7.97 (d,  $J = 8.0$  Hz, 2H), 7.60 (t,  $J = 7.5$  Hz, 1H), 7.46 (t,  $J = 7.5$  Hz, 2H), 7.19–7.36 (m, 22H), 6.95 (t,  $J = 8.5$  Hz, 4H), 6.57 (d,  $J = 9.0$  Hz, 2H), 5.50 (d,  $J = 3.0$  Hz, 1H), 5.32 (t,  $J = 10.0$  Hz, 1H), 4.94 (d,  $J = 12.5$  Hz, 1H), 4.92 (d,  $J = 11.5$  Hz, 1H), 4.68–4.76 (m, 4H), 4.63 (d,  $J = 11.5$  Hz, 1H), 4.46 (d,  $J = 12.5$  Hz, 1H), 4.45 (d,  $J = 12.0$  Hz, 1H), 4.41 (d,  $J = 7.5$  Hz, 1H), 4.40 (d,  $J = 12.0$  Hz, 1H), 4.21 (d,  $J = 12.5$  Hz, 1H), 3.76–3.92 (m, 5H), 3.70 (s, 3H), 3.50–3.60 (m, 5H), 2.57–2.75 (m, 4H), 2.20 (s, 3H), 2.13 (s, 3H);  $^{13}\text{C NMR}$  (125 MHz,  $\text{CDCl}_3$ )  $\delta$  206.3, 171.9, 165.1, 159.1, 138.8, 138.6, 138.5, 137.8, 137.6, 133.0, 132.8, 132.3, 129.9, 129.9, 129.6, 129.6, 129.5, 129.5, 129.3, 129.2, 128.4, 128.3, 128.3, 128.3, 128.2, 127.9, 127.8, 127.5, 127.4, 113.6, 104.0, 86.64, 82.06, 79.49, 76.82, 76.67, 75.08, 74.56, 73.49, 73.40, 73.24, 73.09, 70.42, 69.42, 68.57, 68.48, 67.05, 55.10, 38.14, 29.68, 28.13, 21.00; HRMS (M + Cs) calcd for  $\text{C}_{67}\text{H}_{70}\text{O}_{14}\text{SCs}$  1263.3541, found 1263.3604.

***p*-Methylphenyl 2-*O*-(2,3,4-Tri-*O*-benzyl- $\alpha$ -L-fucopyranosyl)-6-*O*-*tert*-butyldiphenylsilyl-4-*O*-levulinyl-1-thio- $\beta$ -D-galactopyranoside (31).** Compound **31** was prepared from **39** (100 mg) as described for the preparation of **25**, yielding 89 mg (99%) of a syrup:  $^1\text{H NMR}$  (500 MHz,  $\text{CDCl}_3$ )  $\delta$  7.64 (t,  $J = 7.5$  Hz, 4H), 7.22–7.43 (m, 23H), 7.00 (d,  $J = 8.0$  Hz, 2H), 5.50 (d,  $J = 3.0$  Hz, 1H), 4.97 (d,  $J = 3.0$  Hz, 1H), 4.96 (d,  $J = 12.0$  Hz, 1H), 4.86 (d,  $J = 12.0$  Hz, 1H), 4.78 (d,  $J = 12.0$  Hz, 1H), 4.75 (s, 2H), 4.66 (d,  $J = 12.0$  Hz, 1H), 4.64 (d,  $J = 2.5$  Hz, 1H), 4.52 (d,  $J = 9.5$  Hz, 1H), 4.28 (q,  $J = 6.5$  Hz, 1H), 4.04–4.09 (m, 1H), 3.97 (dd,  $J = 10.0, 2.5$  Hz, 1H), 3.83 (dt,  $J = 9.0, 2.5$  Hz, 1H), 3.63–3.75 (m, 4H), 3.57 (t,  $J = 9.0$  Hz, 1H), 2.58–2.70 (m, 2H), 2.51 (t,  $J = 7.0$  Hz, 2H), 2.29 (s, 3H), 2.12 (s, 3H), 1.20 (d,  $J = 6.5$  Hz, 3H), 1.03 (s, 9H);  $^{13}\text{C NMR}$  (125 MHz,  $\text{CDCl}_3$ )  $\delta$  206.3, 171.8, 138.5, 138.4, 137.4, 137.3, 135.6, 133.2, 133.1, 132.3, 129.9, 129.7, 129.6, 129.5, 128.6, 128.4, 128.3, 128.2, 128.0, 127.7, 127.7, 127.6, 127.4, 101.2, 86.6, 79.97, 79.80, 77.76, 77.38, 75.83, 74.73, 74.66, 74.17, 72.52, 69.44, 67.33, 62.08, 38.14, 29.78, 28.05, 26.74, 21.07, 19.10, 16.43; HRMS (M + Cs) calcd for  $\text{C}_{61}\text{H}_{70}\text{O}_{11}\text{SSiCs}$  1171.3462, found 1171.3423.

***p*-Methylphenyl 2-*O*-Benzoyl-4-*O*-(2,3,4-tri-*O*-benzyl- $\alpha$ -L-fucopyranosyl)-6-*O*-*tert*-butyldiphenylsilyl-1-thio- $\beta$ -D-galactopyranoside (32).** Compound **32** was prepared from **41** (48 mg) as described for the preparation of **25**, yielding 26.3 mg (61%):  $^1\text{H NMR}$  (500 MHz,  $\text{CDCl}_3$ )  $\delta$  8.12 (dd,  $J = 8.0, 1.0$  Hz, 2H), 7.65–7.68 (m, 4H), 7.57 (tt,  $J = 7.5, 1.0$  Hz, 1H), 7.16–7.49 (m, 25H), 6.90 (d,  $J = 8.0$  Hz, 2H), 5.33 (t,  $J = 10.0$  Hz, 1H), 5.02 (d,  $J = 11.5$  Hz, 1H), 4.93 (t,  $J = 12.5$  Hz, 2H), 4.84 (d,  $J = 11.5$  Hz, 1H), 4.76 (d,  $J = 12.0$  Hz, 1H), 4.70 (d,  $J = 3.5$  Hz, 1H), 4.67 (d,  $J = 12.0$  Hz, 1H), 4.66 (d,  $J = 10.0$  Hz, 1H), 4.65 (d,  $J = 11.5$  Hz, 1H), 4.00 (dd,  $J = 10.5, 3.5$  Hz, 1H), 3.95 (d,  $J = 3.0$  Hz, 1H), 3.73–3.84 (m, 4H), 3.56–3.62 (m, 2H), 3.47 (d,  $J = 1.5$  Hz, 1H), 2.19 (s, 3H), 1.01 (s, 9H), 0.79 (d,  $J = 6.5$  Hz, 3H);  $^{13}\text{C NMR}$  (125 MHz,  $\text{CDCl}_3$ )  $\delta$  165.5, 138.6, 138.4, 137.5, 137.2, 135.6, 133.7, 133.2, 132.8, 130.4, 129.9, 129.7, 129.2, 128.8, 128.5, 128.4, 128.4, 128.4, 128.2, 128.1, 127.9, 127.7, 127.6, 102.0, 85.7, 80.98, 79.70, 79.25, 77.38, 76.35, 74.67, 74.36, 74.19, 73.14, 71.84, 67.30, 62.86, 29.65, 26.78, 21.10, 16.21; HRMS (M + Cs) calcd for  $\text{C}_{63}\text{H}_{68}\text{O}_{10}\text{SSiCs}$  1177.3357, found 1177.3397.

***p*-Methylphenyl 2,3-Di-*O*-benzoyl-4,6-*O*-benzylidene-1-thio- $\beta$ -D-galactopyranoside (33).** *p*-Methylphenyl 4,6-*O*-benzylidene-1-thio- $\beta$ -D-galactopyranoside (1.0 g, 2.67 mmol) was treated with  $\text{BzCl}$  (2 mL)/pyridine (3 mL) in  $\text{CH}_2\text{Cl}_2$  (10 mL). Chromatography (hexane/AcOEt, 1:1) of the residue gave **33** (1.48 g, 95%):  $[\alpha]_D^{25} + 34^\circ$  (c, 0.5,  $\text{CHCl}_3$ );  $^1\text{H NMR}$  (500 MHz,  $\text{CDCl}_3$ )  $\delta$  5.76 (t, 1H,  $J = 10.0$  Hz, H-2), 5.49 (s, 1H, ArCH), 5.34 (dd, 1H,  $J = 3.5, 10.0$  Hz, H-3), 4.902 (d, 1H,  $J = 10.0$  Hz, H-1), 4.57 (d, 1H,  $J = 3.0$  Hz, H-4), 4.44, 4.08 (dd, 1H each,  $J = 1.5, 12.5$  Hz, H-6), 3.75 (s, 1H, H-5), 2.34 (s, 3H, -Me); HRMS (M + Cs) calcd for  $\text{C}_{34}\text{H}_{30}\text{O}_7\text{SCs}$  715.0767, found 715.0792. Anal. Calcd for  $\text{C}_{34}\text{H}_{30}\text{O}_7\text{S}$ : C, 70.09; H, 5.19; S, 5.50. Found: C, 70.05; H, 5.02; S, 6.06.

***p*-Methylphenyl 4,6-*O*-Benzylidene-2-*O*-chloroacetyl-1-thio- $\beta$ -D-galactopyranoside (34).** To a solution of the *p*-methylphenyl 4,6-*O*-

benzylidene-1-thio- $\beta$ -D-galactopyranoside (2.5 g, 6.68 mmol), DCC (1.65 g, 8.0 mmol), and DMAP (200 mg) in  $\text{CH}_2\text{Cl}_2$  (40 mL) was added levulinic acid (770  $\mu\text{L}$ , 7.35 mmol). The mixture was stirred at room temperature for 3 h, and then pyridine (2.5 mL) and chloroacetyl chloride (537  $\mu\text{L}$ , 13.36 mmol) were added. After being stirred overnight, the mixture was diluted with  $\text{CH}_2\text{Cl}_2$  (150 mL), washed with water, 10%  $\text{H}_2\text{SO}_4$ , water, and saturated aqueous  $\text{NaHCO}_3$ , dried over  $\text{Na}_2\text{SO}_4$ , filtered, and concentrated. The residue was chromatographed (hexane/AcOEt, 2:1 to 1:1) to give *p*-methylphenyl 4,6-*O*-benzylidene-2-*O*-chloroacetyl-3-*O*-levulinyl-1-thio- $\beta$ -D-galactopyranoside (1.32 g, 36%), which was treated with  $\text{NH}_2\text{NH}_2$  (1 mL)/AcOH (2 mL) in THF/MeOH (10:1, 10 mL). The residue was concentrated, diluted with  $\text{CH}_2\text{Cl}_2$  (150 mL), washed with saturated aqueous  $\text{NaHCO}_3$ , dried ( $\text{Na}_2\text{SO}_4$ ), filtered, and concentrated. Chromatography of the residue gave **34** (1.03 g, 95%) as a white solid:  $[\alpha]_D^{25} - 17.6^\circ$  (c, 0.5,  $\text{CHCl}_3$ );  $^1\text{H NMR}$  (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.50–7.10 (9H), 5.47 (s, 1H, ArCH), 5.01 (t, 1H,  $J = 9.64$  Hz, H-2), 4.579 (d, 1H,  $J = 9.76$  Hz, H-1), 4.36 (dd, 1H,  $J = 1.48, 12.48$  Hz, H-6), 4.17 (dd, 1H,  $J = 1.0, 3.64$  Hz, H-4), 4.14 (s, 2H,  $\text{CH}_2\text{Cl}$ ), 3.73 (bs, 1H, H-3), 3.51 (d, 1H,  $J = 1.08$  Hz, H-5), 2.66 (bs, 1H, OH), 2.35 (s, 3H, Me);  $^{13}\text{C NMR}$  (500 MHz,  $\text{CDCl}_3$ )  $\delta$  166.41, 138.53, 137.20, 101.39, 84.29, 75.45, 72.32, 71.76, 69.75, 68.98, 40.84, 21.21; HRMS (M + Cs) calcd for  $\text{C}_{22}\text{H}_{23}\text{O}_6\text{ClSCs}$  473.0802, found 473.0817.

***p*-Methylphenyl 2-*O*-Benzoyl-6-*O*-*tert*-butyldiphenylsilyl-4-*O*-levulinyl-3-*O*-*p*-methoxybenzyl-1-thio- $\beta$ -D-galactopyranoside (35).** Compound **45** (1.97 g, 2.65 mmol) was treated with pyridine (50 mL) and benzoyl chloride (1.2 mL, 10.6 mmol). The residue was subjected to a column chromatography on silica gel (hexanes/EtOAc, 4:1) to give **35** (2.24 g, 100%) as a syrup:  $^1\text{H NMR}$  (500 MHz,  $\text{CDCl}_3$ )  $\delta$  7.98 (d,  $J = 8.0$  Hz, 2H), 7.65–7.68 (m, 4H), 7.60 (t,  $J = 7.5$  Hz, 1H), 7.37–7.48 (m, 8H), 7.32 (d,  $J = 8.0$  Hz, 2H), 7.01 (d,  $J = 9.0$  Hz, 2H), 6.99 (d,  $J = 8.0$  Hz, 2H), 6.59–6.62 (m, 2H), 5.66 (d,  $J = 3.0$  Hz, 1H), 5.31 (t,  $J = 10.0$  Hz, 1H), 4.68 (d,  $J = 10.0$  Hz, 1H), 4.54 (d,  $J = 12.5$  Hz, 1H), 4.33 (d,  $J = 12.5$  Hz, 1H), 3.80–3.85 (m, 1H), 3.68–3.73 (m, 5H), 3.62 (dd,  $J = 9.5, 3.0$  Hz, 1H), 2.55–2.73 (m, 4H), 2.27 (s, 3H), 2.13 (s, 3H), 1.07 (s, 9H);  $^{13}\text{C NMR}$  (125 MHz,  $\text{CDCl}_3$ )  $\delta$  206.1, 171.8, 165.1, 159.1, 137.9, 135.6, 135.6, 133.1, 133.0, 132.9, 129.9, 129.9, 129.8, 129.8, 129.6, 129.5, 129.3, 129.2, 128.3, 127.8, 127.7, 113.5, 87.0, 77.67, 76.87, 70.35, 69.62, 66.16, 61.99, 55.11, 38.18, 29.75, 28.18, 26.74, 21.08, 19.12; HRMS (M + Cs) calcd for  $\text{C}_{49}\text{H}_{54}\text{O}_9\text{SSiCs}$  979.2312, found 979.2349.

***p*-Methylphenyl 2-*O*-Benzoyl-4-*O*-levulinyl-3-*O*-*p*-methoxybenzyl-1-thio- $\beta$ -D-galactopyranoside (36).** A mixture of **35** (330 mg, 0.39 mmol), HF/pyridine complex (3.5 mL), acetic acid (5.0 mL), and dry THF (25 mL) was stirred for 11 h under argon. The reaction mixture was diluted with EtOAc (150 mL) and then washed with saturated aqueous  $\text{NaHCO}_3$  (3  $\times$  30 mL) and brine (30 mL), dried over  $\text{Na}_2\text{SO}_4$ , filtered, and concentrated under reduced pressure. The residue was purified by chromatography on a silica gel column (hexanes/EtOAc, 1:1.5) to yield **36** (237 mg, 100%) as a syrup:  $^1\text{H NMR}$  (500 MHz,  $\text{CDCl}_3$ )  $\delta$  7.99 (dd,  $J = 8.5, 1.0$  Hz, 2H), 7.61 (t,  $J = 7.0, 1.0$  Hz, 1H), 7.47 (t,  $J = 8.0$  Hz, 2H), 7.32–7.34 (m, 2H), 7.06 (d,  $J = 8.0$  Hz, 2H), 7.00 (d,  $J = 9.0$  Hz, 2H), 6.59–6.62 (m, 2H), 5.53 (d,  $J = 3.0$  Hz, 1H), 5.38 (t,  $J = 10.0$  Hz, 1H), 4.70 (d,  $J = 10.0$  Hz, 1H), 4.53 (d,  $J = 12.0$  Hz, 1H), 4.31 (d,  $J = 12.5$  Hz, 1H), 3.77–3.80 (m, 1H), 3.71 (s, 3H), 3.62–3.70 (m, 2H), 2.82–2.89 (m, 1H), 2.67–2.74 (m, 2H), 2.57–2.64 (m, 2H), 2.30 (s, 3H), 2.19 (s, 3H), 2.04 (d,  $J = 0.5$  Hz, 1H);  $^{13}\text{C NMR}$  (125 MHz,  $\text{CDCl}_3$ )  $\delta$  206.9, 173.1, 165.1, 159.2, 138.1, 133.1, 129.9, 129.5, 129.1, 128.8, 128.2, 113.6, 86.86, 77.40, 76.64, 70.37, 69.67, 66.62, 60.51, 55.08, 38.00, 29.70, 28.01, 21.02; HRMS (M + Cs) calcd for  $\text{C}_{33}\text{H}_{36}\text{O}_9\text{SCs}$  741.1134, found 741.1155.

***p*-Methylphenyl 3-*O*-Benzyl-4,6-*O*-benzylidene-2-*O*-levulinyl-1-thio- $\beta$ -D-galactopyranoside (37).** *p*-Methylphenyl 3-*O*-benzyl-4,6-*O*-benzylidene-1-thio- $\beta$ -D-galactopyranoside (300 mg, 0.646 mmol) in  $\text{CH}_2\text{Cl}_2$  (5 mL) was treated with levulinic acid (120  $\mu\text{L}$ , 0.97 mmol), DCC (200 mg), and DMAP (50 mg) according to the procedure described for the preparation of **34**. The residue was purified by column chromatography (hexanes/AcOEt, 1:1) to give **37** (345 mg, 95%) as a white solid:  $[\alpha]_D^{25} - 2.6^\circ$  (c, 0.5,  $\text{CHCl}_3$ );  $^1\text{H NMR}$  (500 MHz,  $\text{CDCl}_3$ )  $\delta$  7.49–7.03 (m, 14 H), 5.42 (s, 1H), 5.26 (t, 1H,  $J = 10.0$  Hz, H-2), 4.65, 4.61 (d, each 1H,  $J = 12.5$  Hz), 4.573 (d, 1H,  $J = 9.5$  Hz, H-1),

4.33 (d, 1H,  $J = 12.0$  Hz), 4.14 (d, 1H,  $J = 3.5$  Hz), 3.97 (d, 1H,  $J = 12.0$  Hz), 3.60 (dd, 1H,  $J = 10.0, 3.5$  Hz), 3.41 (s, 1H), 2.77, 2.62 (m, 2H each), 2.32, 2.19 (s, 3H each);  $^{13}\text{C}$  NMR (125 MHz,  $\text{CDCl}_3$ )  $\delta$  206.4, 171.7, 138.1, 138.0, 137.6, 101.2, 85.3, 78.4, 73.2, 71.2, 69.9, 69.2, 68.6, 37.9, 29.9, 28.1, 21.2; HRMS ( $M + \text{Cs}$ ) calcd for  $\text{C}_{32}\text{H}_{34}\text{O}_7\text{SCs}$  695.1080, found 695.1054.

***p*-Methylphenyl 2,3-Di-*O*-acetyl-6-*O*-benzyl-1-thio- $\beta$ -D-galactopyranoside (38).** *p*-Methylphenyl 4,6-*O*-benzylidene-1-thio- $\beta$ -D-galactopyranoside (200 mg, 0.437 mmol) was treated with  $\text{Ac}_2\text{O}$ /pyridine (1:2, 3 mL). Flash chromatography (hexanes/AcOEt, 1:1) of the residue gave *p*-methylphenyl 2,3-di-*O*-acetyl-4,6-*O*-benzylidene-1-thio- $\beta$ -D-galactopyranoside (358 mg, 97%). One part of the product (200 mg, 0.437 mmol) was mixed with 3-Å molecular sieves (300 mg) and  $\text{NaCNBH}_3$  (155 mg, 2.19 mmol) in THF (2 mL), and 1 M HCl/ $\text{Et}_2\text{O}$  solution was added until no more gas evolved. The mixture was diluted with  $\text{CH}_2\text{Cl}_2$  (20 mL), filtered through Celite, washed with brine, dried ( $\text{Na}_2\text{SO}_4$ ), filtered, and concentrated. Chromatography (hexanes/AcOEt, 1:1) of the residue gave **38** (184 mg, 92%) as a white solid:  $[\alpha]_D^{25} + 7^\circ$  (c, 0.5,  $\text{CHCl}_3$ );  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$  41–7.05 (9H), 5.27 (t, 1H,  $J = 9.5$  Hz, H-2), 4.95 (dd, 1H,  $J = 3.0, 9.5$  Hz, H-3), 4.625 (d, 1H,  $J = 10.0$  Hz, H-1), 4.55 (AB<sub>q</sub>, 2H,  $J = 12.0$  Hz, ArCH<sub>2</sub>), 4.16 (bs, 1H, H-4), 3.77 (m, 2H, H-6), 3.70 (t, 1H,  $J = 5.0$  Hz, H-5), 2.74 (d, 1H,  $J = 3.5$  Hz, OH), 2.30, 2.08, 2.06 (s, 3H each, Me); HRMS ( $M + \text{Na}$ ) calcd for  $\text{C}_{24}\text{H}_{28}\text{O}_7\text{SNa}$  483.1453, found 483.1465.

***p*-Methylphenyl 2-*O*-(2,3,4-Tri-*O*-benzyl- $\alpha$ -L-fucopyranosyl)-6-*O*-tert-butylidiphenylsilyl-4-*O*-levulinyl-3-*O*-*p*-methoxybenzyl-1-thio- $\beta$ -D-galactopyranoside (39).** To a mixture of **45** (300 mg, 0.404 mmol), **50** (327 mg, 0.606 mmol), and 4-Å molecular sieves (800 mg) in  $\text{CH}_2\text{Cl}_2$  (8 mL) was added NIS (143 mg, 0.606 mmol) under argon. After the mixture was stirred for 20 min at  $-20^\circ\text{C}$ , TFOH (65  $\mu\text{L}$ , 0.3 M in  $\text{Et}_2\text{O}$ ) was added at  $-20^\circ\text{C}$ , and the reaction mixture was stirred for 20 min.  $\text{Et}_3\text{N}$  (1.0 mL) was then added. The reaction mixture was filtered through Celite, and the filtrate was diluted with  $\text{CH}_2\text{Cl}_2$ . The solution was washed with saturated aqueous  $\text{Na}_2\text{S}_2\text{O}_5$ , saturated  $\text{NaHCO}_3$ , and brine, dried over  $\text{Na}_2\text{SO}_4$ , and concentrated. The residue was purified by column chromatography on silica gel (hexanes/EtOAc, 4:1) to give **39** (343 mg, 73%):  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$  7.60–7.63 (m, 4H), 7.19–7.43 (m, 23H), 7.06 (d,  $J = 9.0$  Hz, 2H), 7.01 (d,  $J = 8.0$  Hz, 2H), 6.76–6.80 (m, 2H), 5.76 (d,  $J = 4.0$  Hz, 1H), 5.63 (d,  $J = 3.0$  Hz, 1H), 4.94 (d,  $J = 11.5$  Hz, 1H), 4.79 (d,  $J = 11.5$  Hz, 1H), 4.74 (d,  $J = 10.0$  Hz, 1H), 4.72 (d,  $J = 11.5$  Hz, 1H), 4.58–4.69 (m, 5H), 4.26 (d,  $J = 10.5$  Hz, 1H), 3.97–4.07 (m, 3H), 3.76 (s, 3H), 3.71–3.75 (m, 3H), 3.59–3.65 (m, 2H), 2.49–2.56 (m, 4H), 2.29 (s, 3H), 2.07 (s, 3H), 1.14 (d,  $J = 6.5$  Hz, 3H), 1.02 (s, 9H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  171.73, 158.91, 138.76, 138.61, 138.43, 137.23, 135.61, 135.55, 133.17, 132.94, 131.56, 130.42, 129.76, 129.67, 129.58, 128.68, 128.35, 128.29, 128.14, 128.10, 127.70, 127.67, 127.51, 127.40, 127.33, 113.60, 97.57, 87.52, 82.57, 79.47, 77.71, 77.10, 75.55, 74.68, 73.14, 72.81, 71.53, 70.25, 67.37, 65.95, 62.00, 55.22, 38.13, 29.74, 28.08, 26.72, 21.04, 19.06, 16.58; HRMS ( $M + \text{Cs}$ ) calcd for  $\text{C}_{69}\text{H}_{78}\text{O}_{12}\text{SSiCs}$  1291.4038, found 1291.4100.

***p*-Methylphenyl 2-*O*-(2,3,4-Tri-*O*-benzyl- $\alpha$ -L-fucopyranosyl)-4-*O*-levulinyl-3-*O*-*p*-methoxybenzyl-1-thio- $\beta$ -D-galactopyranoside (40).** Compound **40** was prepared from **39** (86.0 mg) as described for the preparation of **36**, yielding 62.6 mg (92%):  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$  7.18–7.37 (m, 17H), 7.09 (d,  $J = 8.0$  Hz, 2H), 7.04 (d,  $J = 8.5$  Hz, 2H), 6.78 (d,  $J = 8.5$  Hz, 2H), 5.76 (d,  $J = 4.0$  Hz, 1H), 5.45 (d,  $J = 3.5$  Hz, 1H), 4.94 (d,  $J = 11.5$  Hz, 1H), 4.80 (d,  $J = 11.5$  Hz, 1H), 4.76 (d,  $J = 10.0$  Hz, 1H), 4.73 (d,  $J = 11.5$  Hz, 1H), 4.58–4.68 (m, 4H), 4.55 (d,  $J = 10.5$  Hz, 1H), 4.27 (d,  $J = 10.5$  Hz, 1H), 4.05–4.09 (m, 3H), 4.00 (dd,  $J = 10.0, 2.5$  Hz, 1H), 3.82 (dd,  $J = 9.0, 3.5$  Hz, 1H), 3.77 (s, 3H), 3.73 (bs, 1H), 3.67 (dd,  $J = 11.5, 6.5$  Hz, 1H), 3.59 (t,  $J = 6.5$  Hz, 1H), 3.51 (dd,  $J = 11.0, 6.5$  Hz, 1H), 2.59–2.75 (m, 3H), 2.50–2.56 (m, 1H), 2.32 (s, 3H), 2.13 (s, 3H), 1.17 (d,  $J = 6.5$  Hz, 3H);  $^{13}\text{C}$  NMR (125 MHz,  $\text{CDCl}_3$ )  $\delta$  206.4, 173.2, 159.0, 138.7, 138.6, 138.3, 137.6, 132.0, 129.8, 129.6, 129.5, 128.5, 128.3, 128.2, 128.1, 128.1, 127.7, 127.5, 127.4, 127.4, 113.6, 97.6, 87.08, 82.10, 79.42, 77.66, 76.75, 75.51, 74.68, 73.15, 72.82, 71.79, 70.13, 67.40, 66.41, 60.53, 55.20, 37.93, 29.70, 27.92, 21.04, 16.58; HRMS ( $M + \text{Cs}$ ) calcd for  $\text{C}_{53}\text{H}_{60}\text{O}_{12}\text{SCs}$  1053.2860, found 1053.2830.

***p*-Methylphenyl 2-*O*-Benzoyl-4-*O*-(2,3,4-tri-*O*-benzyl- $\alpha$ -L-fucopyranosyl)-6-*O*-tert-butylidiphenylsilyl-3-*O*-*p*-methoxybenzyl-1-thio- $\beta$ -D-galactopyranoside (41).** Compound **41** was prepared from **44** (311 mg) and **50** (337 mg) as described for the preparation of **39**, yielding 356 mg (74%):  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$  8.02 (dd,  $J = 8.0, 1.0$  Hz, 2H), 7.69 (dd,  $J = 8.0, 1.0$  Hz, 2H), 7.63 (dd,  $J = 8.0, 1.5$  Hz, 2H), 7.59 (t,  $J = 7.5$  Hz, 1H), 7.17–7.48 (m, 25H), 6.98 (t,  $J = 8.5$  Hz, 4H), 6.63 (d,  $J = 8.5$  Hz, 2H), 5.76 (t,  $J = 9.5$  Hz, 1H), 5.57 (d,  $J = 4.0$  Hz, 1H), 4.92 (d,  $J = 12.0$  Hz, 1H), 4.87 (d,  $J = 11.5$  Hz, 1H), 4.77 (d,  $J = 12.0$  Hz, 2H), 4.67 (d,  $J = 12.0$  Hz, 1H), 4.56 (d,  $J = 11.5$  Hz, 1H), 4.49 (d,  $J = 11.5$  Hz, 1H), 4.44 (d,  $J = 12.5$  Hz, 1H), 4.39 (d,  $J = 11.5$  Hz, 1H), 4.21 (d,  $J = 2.0$  Hz, 1H), 3.96 (dd,  $J = 11.0, 7.5$  Hz, 1H), 3.89 (dd,  $J = 10.5, 4.0$  Hz, 1H), 3.63–3.77 (m, 7H), 3.44 (q,  $J = 6.5$  Hz, 1H), 3.34 (d,  $J = 2.0$  Hz, 1H), 2.21 (s, 3H), 1.07 (s, 9H), 0.74 (d,  $J = 6.5$  Hz, 3H);  $^{13}\text{C}$  NMR (125 MHz,  $\text{CDCl}_3$ )  $\delta$  164.9, 159.2, 139.4, 139.0, 138.6, 137.0, 135.7, 135.5, 133.4, 133.0, 132.9, 131.6, 130.9, 130.3, 129.8, 129.7, 129.6, 129.5, 129.3, 128.6, 128.3, 128.2, 128.1, 128.1, 127.9, 127.7, 127.5, 127.5, 127.2, 126.8, 113.7, 96.6, 87.8, 81.27, 80.23, 78.32, 77.51, 77.21, 75.12, 74.50, 73.61, 71.83, 71.46, 70.32, 69.22, 66.63, 64.76, 55.15, 26.84, 21.04, 16.54; HRMS ( $M + \text{Cs}$ ) calcd for  $\text{C}_{71}\text{H}_{76}\text{O}_{11}\text{SSiCs}$  1297.3932, found 1297.3995.

***p*-Methylphenyl 2-*O*-Benzoyl-4,6-*O*-benzylidene-1-thio- $\beta$ -D-galactopyranoside (42).** *p*-Methylphenyl 4,6-*O*-benzylidene-1-thio- $\beta$ -D-galactopyranoside (300 mg, 0.802 mmol) in  $\text{CH}_2\text{Cl}_2$  (10 mL) was treated with DCC (238 mg, 1.16 mmol), DMAP (50 mg), and levulinic acid (100  $\mu\text{L}$ , 0.963 mmol) as described for the preparation of **34**. The residue was treated with pyridine (500  $\mu\text{L}$ ) and  $\text{BzCl}$  (400  $\mu\text{L}$ ) under reflux conditions. After workup, the residue was chromatographed (hexanes/AcOEt, 2:1 to 1:1) to give *p*-methylphenyl 2-*O*-benzoyl-4,6-*O*-benzylidene-3-*O*-levulinyl-1-thio- $\beta$ -D-galactopyranoside (226 mg, 49%), which was treated with  $\text{NH}_2\text{NH}_2$  (100  $\mu\text{L}$ )/AcOH (200  $\mu\text{L}$ ) in THF/MeOH (10:1, 5 mL). The residue was concentrated, diluted with  $\text{CH}_2\text{Cl}_2$  (150 mL), washed with saturated aqueous  $\text{NaHCO}_3$ , dried ( $\text{Na}_2\text{SO}_4$ ), filtered, and concentrated. Chromatography of the residue gave **42** (185 mg, 99%):  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$  7.50–7.10 (14H), 5.52 (s, 1H, ArCH), 5.20 (t, 1H,  $J = 9.5$  Hz, H-2), 4.760 (d, 1H,  $J = 10.0$  Hz, H-1), 4.40 (dd, 1H,  $J = 1.5, 12.5$  Hz, H-6), 4.24 (bd, 1H,  $J = 3.5$  Hz, H-4), 4.04 (dd, 1H,  $J = 1.5, 12.5$  Hz, H-6), 3.87 (ddd, 1H,  $J = 3.0, 9.5$  Hz, H-3) 3.59 (bs, 1H, H-5), 2.62 (d, 1H,  $J = 11.0$  Hz, OH), 2.35 (s, 3H, Me);  $^{13}\text{C}$  NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$  165.96, 101.44, 84.80, 75.60, 72.90, 70.67, 69.88, 69.10, 21.21; HRMS ( $M + \text{Na}$ ) calcd for  $\text{C}_{27}\text{H}_{26}\text{O}_6\text{SNa}$  501.1348, found 501.1364.

***p*-Methylphenyl 2-*O*-benzoyl-6-*O*-tert-butylidiphenylsilyl-3-*O*-*p*-methoxybenzyl-1-thio- $\beta$ -D-galactopyranoside (44).** To a stirred solution of **35** (420 mg, 0.496 mmol) in THF/MeOH (10:1 v/v, 22 mL) was added 1 M  $\text{NH}_2\text{NH}_2$ /AcOH (1:2.5 v/v) in THF/MeOH (5:1 v/v) (5 mL). The reaction mixture was stirred for 4 h and then evaporated to dryness. The residue was diluted with EtOAc (80 mL), washed with saturated aqueous  $\text{NaHCO}_3$  and brine, and dried over  $\text{Na}_2\text{SO}_4$ . The dried organic layer was concentrated under reduced pressure, and the residue was purified by chromatography on a silica gel column (hexanes/EtOAc, 4:1) to give **44** (343 mg, 92%) as solids:  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$  8.01 (dd,  $J = 8.0, 1.0$  Hz, 2H), 7.68–7.71 (m, 4H), 7.60 (t,  $J = 7.0, 1.5$  Hz, 1H), 7.36–7.48 (m, 8H), 7.33 (d,  $J = 8.0$  Hz, 2H), 7.07 (d,  $J = 8.5$  Hz, 2H), 6.99 (d,  $J = 8.0$  Hz, 2H), 6.67 (d,  $J = 9.0$  Hz, 2H), 5.43 (t,  $J = 10.0$  Hz, 1H), 4.67 (d,  $J = 10.0$  Hz, 1H), 4.57 (d,  $J = 12.0$  Hz, 1H), 4.45 (d,  $J = 12.0$  Hz, 1H), 4.12 (bs, 1H), 3.94–4.00 (m, 2H), 3.71 (s, 3H), 3.61 (dd,  $J = 9.0, 3.0$  Hz, 1H), 3.56 (t,  $J = 6.0$  Hz, 1H), 2.54 (d,  $J = 1.0$  Hz, 1H), 2.27 (s, 3H), 1.07 (s, 9H);  $^{13}\text{C}$  NMR (125 MHz,  $\text{CDCl}_3$ )  $\delta$  165.2, 159.3, 137.7, 135.6, 135.6, 133.2, 133.2, 133.0, 132.6, 130.1, 129.9, 129.7, 129.5, 129.5, 129.3, 128.3, 127.7, 113.8, 87.06, 79.02, 78.75, 71.01, 69.85, 66.30, 63.15, 55.12, 26.81, 21.08, 19.19; HRMS ( $M + \text{Cs}$ ) calcd for  $\text{C}_{44}\text{H}_{48}\text{O}_7\text{SSiCs}$  881.1944, found 881.1976.

***p*-Methylphenyl 6-*O*-tert-Butylidiphenylsilyl-4-*O*-levulinyl-3-*O*-*p*-methoxybenzyl-1-thio- $\beta$ -D-galactopyranoside (45).** A mixture of *p*-methylphenyl 2-*O*-chloroacetyl-3-*O*-*p*-methoxybenzyl-4-*O*-levulinyl-6-*O*-tert-butylidiphenylsilyl-1-thio- $\beta$ -D-galactopyranoside<sup>22</sup> (550 mg, 0.672 mmol), saturated  $\text{NaHCO}_3$  in MeOH/ $\text{H}_2\text{O}$  (5:1 v/v) solution (50 mL), and THF (12 mL) was stirred for 6 h at  $60^\circ\text{C}$ . The solvent was



then removed under reduced pressure, and the residue was diluted with EtOAc (150 mL) and water (30 mL). The organic layer was separated, and the aqueous layer was extracted with EtOAc (2 × 25 mL). The organic fractions were combined, washed with brine, and dried over Na<sub>2</sub>SO<sub>4</sub>. The dried organic layer was concentrated, and the residue was purified by chromatography on a silica gel column (hexanes/EtOAc, 3:1) to yield **45** (498 mg, 100%) as a syrup: <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.63–7.66 (m, 4H), 7.36–7.45 (m, 8H), 7.26 (d, *J* = 8.5 Hz, 2H), 7.04 (d, *J* = 8.0 Hz, 2H), 6.87 (d, *J* = 8.5 Hz, 2H), 5.63 (d, *J* = 3.0 Hz, 1H), 4.71 (d, *J* = 11.0 Hz, 1H), 4.46 (d, *J* = 9.5 Hz, 1H), 4.40 (d, *J* = 11.0 Hz, 1H), 3.79 (s, 3H), 3.78 (dd, *J* = 12.5, 9.0 Hz, 1H), 3.64–3.68 (m, 2H), 3.62 (dt, *J* = 1.5, 9.5 Hz, 1H), 3.44 (dd, *J* = 9.0, 3.0 Hz, 1H), 2.50–2.67 (m, 4H), 2.42 (d, *J* = 1.5 Hz, 1H), 2.30 (s, 3H), 2.12 (s, 3H), 1.05 (s, 9H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 205.9, 171.7, 159.4, 138.1, 135.6, 135.6, 133.1, 133.0, 129.9, 129.8, 129.8, 129.6, 129.4, 128.2, 127.7, 113.9, 88.4, 79.83, 77.58, 71.17, 68.38, 66.21, 61.89, 55.25, 38.06, 29.79, 28.02, 26.74, 21.10, 19.10; HRMS (M + Cs) calcd for C<sub>42</sub>H<sub>50</sub>O<sub>8</sub>SSiCs 875.2050, found 875.2082.

***p*-Methylphenyl 2,3-Di-*O*-benzyl-4,6-*O*-benzylidene-1-thio-β-*D*-galactopyranoside (46) and *p*-Methylphenyl 2-*O*-Benzyl-4,6-*O*-benzylidene-1-thio-β-*D*-galactopyranoside (49).** To a mixture of *p*-methylphenyl 4,6-*O*-benzylidene-1-thio-β-*D*-galactopyranoside (2.0 g, 5.35 mmol) and BnBr (1.08 mL, 6.42 mmol) in a mixture of CH<sub>2</sub>Cl<sub>2</sub> (75 mL) and 1.0 M aqueous NaOH (27 mL) was added Bu<sub>4</sub>N/H<sub>2</sub>SO<sub>4</sub> (367 mg, 1.07 mmol). The mixture was stirred vigorously for 20 h under reflux and then diluted with CH<sub>2</sub>Cl<sub>2</sub> (100 mL), washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. Chromatography (hexanes/AcOEt, 5:1 to 1:1) of the residue gave dibenzylated **46** (170 mg, 6%) as a syrup: [α]<sub>D</sub><sup>25</sup> −23° (c, 0.5, CHCl<sub>3</sub>); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 5.48 (s, 1H, ArCH), 4.72 (m, 4H, ArCH<sub>2</sub>), 4.577 (d, 1H, *J* = 9.5 Hz, H-1), 4.37 (dd, 1H, *J* = 1.5, 12.0 Hz, H-6), 4.14 (d, 1H, *J* = 3.5 Hz, H-4), 3.98 (dd, 1H, *J* = 1.5, 12.5 Hz, H-6), 3.85 (t, 1H, *J* = 9.5 Hz, H-2), 3.63 (dd, 1H, *J* = 3.5, 9.5 Hz, H-3), 3.40 (bs, 1H, H-5), 3.51 (d, 1H, *J* = 1.08 Hz, H-5), 2.31 (s, 3H, Me); <sup>13</sup>C NMR (500 MHz, CDCl<sub>3</sub>) δ 138.5, 138.1, 137.9, 137.6, 133.4, 101.3, 86.5, 81.4, 75.4, 75.3, 73.6, 71.8, 69.7, 69.4, 21.1. Data for *p*-methylphenyl 3-*O*-benzyl-4,6-*O*-benzylidene-1-thio-β-*D*-galactopyranoside (1.10 g, 44.7%): <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 5.39 (s, 1H, ArCH), 4.68 (m, 2H, ArCH<sub>2</sub>), 4.435 (d, 1H, *J* = 9.5 Hz, H-1), 4.30 (dd, 1H, *J* = 1.0, 12.5 Hz, H-6), 4.09 (d, 1H, *J* = 3.5 Hz, H-4), 3.92 (dd, 1H, *J* = 1.5, 12.5 Hz, H-6), 3.85 (t, 1H, *J* = 9.5 Hz, H-2), 3.47 (dd, 1H, *J* = 3.5, 9.5 Hz, H-3), 3.38 (bs, 1H, H-5), 2.31 (s, 3H, Me); <sup>13</sup>C NMR (500 MHz, CDCl<sub>3</sub>) δ 101.0, 87.0, 80.1, 73.2, 71.5, 69.9, 69.3, 67.0, 21.2; HRMS (M + Na) calcd for C<sub>27</sub>H<sub>28</sub>O<sub>5</sub>SCs 597.0712, found 597.0728. **49** (780 mg, 31.4%) was formed as syrup: <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 5.51 (s, 1H, ArCH), 4.77 and 4.67 (d, 1H each, ArCH<sub>2</sub>), 4.541 (d, 1H, *J* = 9.9 Hz, H-1), 4.34 (bd, 1H, *J* = 12.0 Hz, H-6), 4.12 (d, 1H, *J* = 3.5 Hz, H-4), 3.97 (bd, 1H, *J* = 12.5 Hz, H-6), 3.60 (t, 1H, *J* = 9.0 Hz, H-2), 3.75 (bs, 1H, H-3), 3.40 (bs, 1H, H-5), 2.60 (bs, 1H, OH), 2.33 (s, 3H, Me); <sup>13</sup>C NMR (500 MHz, CDCl<sub>3</sub>) δ 101.3, 86.3, 77.0, 75.7, 75.2, 74.2, 69.6, 69.2, 21.1; HRMS (M + Cs) calcd for C<sub>27</sub>H<sub>28</sub>O<sub>5</sub>SCs 597.0712, found 597.0727.

***p*-Methylphenyl 2-*O*-(2,3,4-Tri-*O*-benzyl-α-*L*-fucopyranosyl)-6-*O*-*tert*-butyldiphenylsilyl-3-*O*-*p*-methoxybenzyl-1-thio-β-*D*-galactopyranoside (47).** Compound **47** was prepared from **39** (73.0 mg) as described for the preparation of **44**, yielding 57.3 mg (86%): <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.63–7.65 (m, 4H), 7.22–7.41 (m, 23H), 7.13 (d, *J* = 8.5 Hz, 2H), 7.00 (d, *J* = 8.0 Hz, 2H), 6.80 (d, *J* = 8.5 Hz, 2H), 5.75 (d, *J* = 3.5 Hz, 1H), 4.95 (d, *J* = 12.0 Hz, 1H), 4.80 (d, *J* = 11.5 Hz, 1H), 4.65–4.77 (m, 5H), 4.60 (q, *J* = 6.5 Hz, 1H), 4.53 (d, *J* = 11.5 Hz, 1H), 4.43 (d, *J* = 11.5 Hz, 1H), 4.01–4.12 (m, 4H), 3.83–3.89 (m, 2H), 3.76 (s, 3H), 3.67–3.73 (m, 2H), 3.45 (t, *J* = 6.0 Hz, 1H), 2.36 (bs, 1H), 2.28 (s, 3H), 1.14 (d, *J* = 6.0 Hz, 3H), 1.02 (s, 9H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 159.2, 138.8, 138.6, 138.5, 137.0, 135.6, 135.5, 135.5, 133.2, 133.1, 131.4, 130.7, 129.7, 129.6, 129.5, 129.3, 128.7, 128.4, 128.3, 128.1, 127.8, 127.7, 127.5, 127.4, 113.9, 97.6, 87.34, 84.24, 79.59, 78.00, 77.66, 75.70, 74.66, 73.37, 72.78, 71.55, 70.38, 67.31, 65.54, 63.04, 55.19, 29.66, 26.76, 21.04, 16.55; HRMS (M + Cs) calcd for C<sub>64</sub>H<sub>72</sub>O<sub>10</sub>SSiCs 1193.3670, found 1193.3613.

***p*-Methylphenyl 2,3,4,6-Tetra-*O*-benzyl-1-thio-β-*D*-galactopyranoside (48).** *p*-Methylphenyl 1-thio-β-*D*-galactopyranoside (1.0 g, 3.5 mmol) was dissolved in dry DMF (15 mL) and cooled to −10 °C. At this temperature, NaH (840 mg, 35 mmol) was added, and the mixture was allowed to warm to room temperature and stirred for an additional 10 min. Then BnBr (4.1 mL, 35 mmol) was added, and the mixture was stirred for 5 h. At 0 °C, 10 mL of H<sub>2</sub>O was added, and the mixture was extracted with EtOAc (3 × 50 mL). The organic layer was dried over MgSO<sub>4</sub> and evaporated to dryness. Flash chromatography using hexanes/EtOAc (5:1) gave the title compound as a white solid (2.01 g, 89%): [α]<sub>D</sub><sup>22</sup> −1.2° (c, 0.5, CHCl<sub>3</sub>); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.27 (s, 3H), 3.56–3.65 (m, 4H), 3.89 (t, 1H, *J* = 9.4 Hz), 3.97 (s, 1H), 4.42 (AB<sub>q</sub>, 2H, *J* = 11.6 Hz), 4.59–4.60 (m, 3H), 4.70 (m, 3H), 4.73 (AB<sub>q</sub>, 2H, *J* = 10.1 Hz), 4.95 (d, 1H, *J* = 11.5 Hz), 6.98 (d, 2H, *J* = 8.6 Hz), 7.25–7.47 (m, 22H); <sup>13</sup>C NMR (400 MHz, CDCl<sub>3</sub>) δ 21.04, 68.68, 72.63, 73.48, 74.34, 75.54, 77.16, 77.24, 84.13, 87.95, 127.36, 127.49, 127.60, 127.65, 127.71, 127.78, 127.86, 128.09, 128.26, 128.35, 129.49, 132.10; HRMS (M + Cs) calcd for C<sub>41</sub>H<sub>42</sub>O<sub>5</sub>SCs 779.1807, found 779.1782.

***p*-Methylphenyl 2,3,4-Tri-*O*-benzyl-1-thio-β-*L*-fucopyranoside (50).** *p*-Methylphenyl 2,3,4-tri-*O*-acetyl-1-thio-β-*L*-fucopyranoside<sup>9</sup> (2.5 g, 6.31 mmol) was treated with NaOMe/MeOH. The product was further treated with 85% NaH (463 mg, 22.7 mmol) and BnBr (5.8 mL, 37.86 mmol) in DMF (25 mL). After the reaction was finished, hexane (30 mL) and water (300 mL) were added into the vigorously stirred solution. The solid product was filtered and washed with water (2 × 5 mL) and hexanes/AcOEt (15:1, 2 × 5 mL). The crude product was suspended in a hot (70 °C) mixture of AcOEt/hexanes (10:1), stirred for 10 min, cooled to room temperature, and filtered to give pure **50** (2.6 g, 76%) as a solid: [α]<sub>D</sub><sup>22</sup> +8° (c, 0.5, CHCl<sub>3</sub>); HRMS (M + Cs) calcd for C<sub>34</sub>H<sub>36</sub>O<sub>4</sub>SCs 672.1290, found 672.1287.

**Methyl 2,3-Di-*O*-acetyl-6-*O*-benzyl-4-*O*-[2,4,6-tri-*O*-benzoyl-3-*O*-(2,3,4,6-tetra-*O*-benzyl-α-*D*-galactopyranosyl)-β-*D*-galactopyranosyl]-α-*D*-glucopyranoside (52).** A mixture of **48** (37.5 mg, 0.052 mmol), **19** (24 mg, 0.039 mmol), and MS-AW-300 (400 mg) in CH<sub>2</sub>Cl<sub>2</sub> (2 mL) was stirred at 0 °C for 15 min, and then NIS (13.5 mg, 0.057 mmol) was added, followed by 0.5 M TfOH in Et<sub>2</sub>O (10 μL, 0.005 mmol). After 30 min, a solution of **51** (36 mg, 0.080 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (0.5 mL) and MS AW-300 (100 mg) was added, followed by NIS (13.5 mg, 0.057 mmol). The mixture was stirred for 2 h at room temperature, and then solid Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub>, NaHCO<sub>3</sub>, and two drops of H<sub>2</sub>O were added, and the mixture was stirred for 5 min, diluted with CH<sub>2</sub>Cl<sub>2</sub> (25 mL), filtered through Celite, washed with brine, dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated. Chromatography (hexanes/AcOEt, 2:1 to 1:1) of the residue gave **52** (35.9 mg, 64%) as a syrup: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 5.80 (d, 1H, *J* = 3.1 Hz), 5.56 (dd, 1H, *J* = 8.4, 10.1 Hz), 5.48 (d, 1H, *J* = 9.8 Hz), 5.09 (d, 1H, *J* = 3.2 Hz), 4.86 (d, 1H, *J* = 3.6 Hz), 4.79 (dd, 1H, *J* = 3.7, 10.4 Hz), 4.69 (d, 1H, *J* = 11.4 Hz), 4.60 (d, 1H, *J* = 8.1 Hz), 4.58 (d, 1H, *J* = 12.0 Hz), 3.95 (m, 2H), 3.85 (dd, 1H, *J* = 3.2 Hz), 3.81–3.74 (m, 2H), 3.69 (m, 2H), 3.28 (s, 3H), 2.05, 1.96 (s, 3H each); <sup>13</sup>C NMR (500 MHz, CDCl<sub>3</sub>) δ 170.3, 169.7, 166.1, 165.8, 164.3, 243.6, 243.3, 243.0, 138.8, 138.6, 138.2, 138.1, 100.7, 96.9, 95.6, 78.8, 75.1, 75.0, 74.5, 74.3, 73.4, 73.3, 73.1, 72.5, 71.5, 71.4, 71.3, 70.0, 69.9, 69.7, 68.9, 67.6, 86.6, 62.3, 20.9, 20.7; HRMS (M + Cs) calcd for C<sub>79</sub>H<sub>80</sub>O<sub>21</sub>Cs 1497.4246, found 1497.4362.

**Methyl 2,3-Di-*O*-acetyl-6-*O*-benzyl-4-*O*-[2,3,4-tri-*O*-benzoyl-6-*O*-(3,4,6-tri-*O*-acetyl-2-deoxy-2-(2,2,2-trichloroethoxycarbonylamino)-β-*D*-glucopyranosyl)-β-*D*-galactopyranosyl]-α-*D*-glucopyranoside (53).** A mixture of **21** (70 mg, 0.12 mmol), **13** (48 mg, 0.08 mmol), and MS-AW-300 (400 mg) in CH<sub>2</sub>Cl<sub>2</sub> (2 mL) was stirred at 0 °C for 15 min, and then NIS (30.5 mg, 0.132 mmol) was added, followed by a 0.1 M solution of TfOH (5 μL) in Et<sub>2</sub>O. After 15 min, a solution of **51** (72 mg, 0.16 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (0.5 mL) and MS AW-300 (100 mg) was added, followed by NIS (33 mg, 0.13 mmol). The mixture was stirred for 1 h, followed by workup as described in the preparation of **52**. Chromatography (hexanes/AcOEt, 3:2 to 1:1) of the residue gave **53** (62.5 mg, 60%) as a white solid: <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 5.80 (d, 1H, *J* = 3.1 Hz), 5.77 (d, 1H, *J* = 8.2 Hz), 5.56 (dd, 1H, *J* = 8.2, 10.0 Hz), 5.42 (t, 1H, *J* = 10.0 Hz), 5.34 (bt, 1H, *J* = 9.4 Hz), 5.25 (dd, 1H, *J* = 3.2, 10.3 Hz), 5.0 (m, 3H), 4.87 (d, 1H, *J* = 3.5 Hz),



4.75 (d, 1H,  $J = 12.5$  Hz), 4.70 (d, 1H,  $J = 8.3$  Hz), 4.38 (d, 1H,  $J = 12.5$  Hz), 3.31 (s, 3H), 2.07, 2.06 (s, 3H each), 2.01 (s, 9H);  $^{13}\text{C}$  NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$  170.6, 170.4, 169.6, 169.5, 165.4, 165.3, 164.6, 133.6, 133.3, 133.2, 100.7, 100.1, 97.1, 74.3, 74.2, 73.6, 72.5, 72.0, 71.8, 71.6, 70.8, 70.7, 70.0, 69.6, 68.6, 68.2, 67.6, 67.1, 61.8, 56.2, 55.3, 31.6, 29.7, 29.6, 22.63, 21.22, 20.8, 20.6; HRMS ( $M + \text{Cs}$ ) calcd for  $\text{C}_{60}\text{H}_{64}\text{O}_{25}\text{NSiCs}$  1436.1887, found 1436.1824.

**Methyl 2,3-Di-*O*-acetyl-6-*O*-benzyl-4-*O*-[2-*O*-benzyl-4,6-*O*-benzylidene-3-*O*-(2,3,4-tri-*O*-benzyl- $\alpha$ -L-fucopyranosyl)- $\alpha$ -D-galactopyranosyl]- $\alpha$ -D-glucopyranoside (54).** To a cold (0 °C) solution of **50** (32 mg, 0.6 mmol), **49** (19 mg, 0.04 mmol), 2,6-di-*tert*-butyl-4-methylpyridine (25 mg, 0.12 mmol), and MS-AW-300 (300 mg) in  $\text{CH}_2\text{Cl}_2$  (2 mL) was added freshly prepared 1 M DMTST in  $\text{CH}_2\text{Cl}_2$  (120  $\mu\text{L}$ , 0.12 mmol). After 1 h, a solution of methyl 2,3-di-*O*-acetyl-6-*O*-benzyl- $\alpha$ -D-glucopyranoside **51** (36 mg, 0.08 mmol) in  $\text{CH}_2\text{Cl}_2$  (0.5 mL) and MS AW-300 (100 mg) was added, followed by addition of 1 M DMTST (120  $\mu\text{L}$ , 0.12 mmol). The mixture was stirred for 2 h and then diluted with  $\text{CH}_2\text{Cl}_2$  (25 mL), filtered through Celite, washed with saturated aqueous  $\text{NaHCO}_3$ , dried ( $\text{Na}_2\text{SO}_4$ ), filtered, and concentrated. The residue was chromatographed (hexanes/AcOEt, 3:1 to 1:1) to give **54** (28.4 mg, 63%) as a syrup:  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$  5.53 (t, 1H,  $J = 9.5$  Hz), 5.33 (s, 1H), 5.32 (d, 1H,  $J = 3.0$  Hz), 5.14 (d, 1H,  $J = 3.5$  Hz), 4.92–4.49 (m, 12 H), 4.28 (dd, 1H,  $J = 3.0$ , 10.0 Hz), 4.10 (t, 1H,  $J = 9.5$  Hz), 3.87 (dd, 1H,  $J = 3.0$ , 10.0 Hz), 3.72 (bt, 1H,  $J = 12.5$  Hz), 3.39 (s, 3H), 2.07, 2.06 (s, 3H each), 0.97 (d, 1H,  $J = 6.5$  Hz); HRMS ( $M + \text{Cs}$ ) calcd for  $\text{C}_{65}\text{H}_{72}\text{O}_{17}\text{Cs}$  1257.3824, found 1257.3870.

**Methyl 2,3-Di-*O*-acetyl-6-*O*-benzyl-4-*O*-{2,3,4-tri-*O*-benzoyl-6-*O*-[3,6-di-*O*-benzoyl-2-deoxy-2-(2,2,2-trichloroethoxycarbonylamino)-4-*O*-(2,3,4,6-tetra-*O*-benzyl- $\beta$ -D-galactopyranosyl)- $\beta$ -D-glucopyranosyl]- $\beta$ -D-galactopyranosyl]- $\alpha$ -D-glucopyranoside (55).** A mixture of **48** (73 mg, 0.112 mmol), **27** (50 mg, 0.075 mmol), and MS-AW-300 (400 mg) in  $\text{CH}_2\text{Cl}_2$  (3 mL) was stirred at –25 °C for 20 min, and then NIS (27.8 mg, 0.118 mmol) was added, followed by 1 M TFOH (10  $\mu\text{L}$ , 0.001 mmol). After 20 min, **13** (68.8 mg, 0.112 mmol), MS AW-300 (100 mg), and NIS (18.6 mg, 0.079 mmol) were added. The mixture was stirred at 0 °C for 1 h, and then a solution of **51** (250  $\mu\text{L}$  of 125 mg/0.5 mL, 0.150 mmol) and NIS (40 mg, 0.169 mmol) was added, stirred for 50 min, and worked up as described in the preparation of **52**. Chromatography (hexanes/AcOEt, 3:2 to 1:1) of the residue gave **55** (56 mg, 39.2%) as a syrup:  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$  5.80 (d, 1H,  $J = 3.1$  Hz), 5.59 (t, 1H,  $J = 9.5$  Hz), 5.52 (dd, 1H,  $J = 8.2$ , 10.0 Hz), 5.41 (t, 1H,  $J = 9.1$  Hz), 5.24 (dd, 1H,  $J = 3.2$ , 10.4 Hz), 5.03 (d, 1H,  $J = 3.4$  Hz), 5.25 (dd, 1H,  $J = 3.2$ , 10.3 Hz), 4.94 (dd, 1H,  $J = 3.5$ , 10.0 Hz), 4.67 (d, 1H,  $J = 7.9$  Hz), 3.29 (s, 3H), 2.07, 2.02 (s, 3H each), 2.01 (s, 9H); HRMS ( $M + \text{Cs}$ ) calcd for  $\text{C}_{102}\text{H}_{102}\text{O}_{29}\text{NCl}_3\text{Cs}$  2042.4657, found 2042.

**5-Methoxycarbonylpentyl 3-*O*-Benzyl-2-deoxy-6-*O*-*p*-methoxybenzyl-2-phthalimido- $\beta$ -D-glucopyranoside (56).** The title compound was prepared via a three-step procedure: (1) **61b** (16.0 g, 36.6 mmol) in dry acetonitrile (200 mL) was treated with anisaldehyde dimethyl acetyl (9.3 mL, 54.9 mmol) and 10-camphorsulfonic acid (173.5 mg) as described for the preparation of **10**. The residue was subjected to column chromatography on silica gel (hexanes/EtOAc, 2:1) to give 5-methoxycarbonylpentyl 2-deoxy-4,6-*O*-*p*-methoxybenzylidene-2-phthalimido- $\beta$ -D-glucopyranoside (16.4 g, 81%) as solids:  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.84–7.87 (m, 2H), 7.71–7.75 (m, 2H), 7.42 (d,  $J = 8.7$  Hz, 2H), 6.89 (d,  $J = 8.8$  Hz, 2H), 5.52 (s, 1H), 5.24 (d,  $J = 8.5$  Hz, 1H), 4.57–4.63 (m, 1H), 4.36 (dd,  $J = 10.2$ , 4.3 Hz, 1H), 4.22 (dd,  $J = 10.5$ , 8.5 Hz, 1H), 3.78–3.85 (m, 5H), 3.55–3.66 (m, 5H), 3.37–3.45 (m, 1H), 2.64 (d,  $J = 3.5$  Hz, 1H), 1.93–2.07 (m, 2H), 1.32–1.51 (m, 4H), 1.05–1.15 (m, 2H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  173.86, 160.24, 134.13, 131.56, 129.40, 127.59, 123.42, 113.69, 101.83, 98.81, 82.19, 69.66, 68.62, 68.58, 66.09, 56.53, 55.27, 51.39, 33.67, 28.91, 25.24, 24.34; HRMS ( $M + \text{Cs}$ ) calcd for  $\text{C}_{29}\text{H}_{33}\text{O}_{10}\text{NCs}$  688.1159, found 688.1188.

(2) To a solution of the product (8.85 g, 15.9 mmol) from step (1) in dry DMF (40 mL) was added NaH (60%, 0.95 g, 23.8 mmol) in portions. After the mixture was stirred for 10 min, benzyl bromide (2.9 mL, 23.8 mmol) and  $\text{Bu}_4\text{NI}$  (3.5 g, 9.5 mmol) were added at 0 °C. The reaction mixture was stirred for 3 h at 0 °C, and then MeOH (8 mL)

was added, and the mixture was stirred for 10 min. The reaction mixture was poured into ice–water (200 mL) and extracted with EtOAc (3  $\times$  150 mL). The combined organic liquid was dried over  $\text{Na}_2\text{SO}_4$ . The solvent was removed and the residue subjected to column chromatography on silica gel (hexanes/EtOAc, 3:1) to give 5-methoxycarbonylpentyl 3-*O*-benzyl-2-deoxy-4,6-*O*-*p*-methoxybenzylidene-2-phthalimido- $\beta$ -D-glucopyranoside (5.56 g, 54%) as a white solid:  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$  7.66–7.85 (m, 4H), 7.45 (d,  $J = 8.5$  Hz, 2H), 7.00 (dd,  $J = 8.0$ , 1.5 Hz, 2H), 6.86–6.94 (m, 5H), 5.58 (s, 1H), 5.18 (d,  $J = 8.5$  Hz, 1H), 4.78 (d,  $J = 12.5$  Hz, 1H), 4.49 (d,  $J = 12.5$  Hz, 1H), 4.40 (dd,  $J = 10.5$ , 9.0 Hz, 1H), 4.38 (dd,  $J = 10.5$ , 5.5 Hz, 1H), 4.20 (dd,  $J = 10.5$ , 8.5 Hz, 1H), 3.74–3.86 (m, 6H), 3.58–3.67 (m, 4H), 3.38 (dt,  $J = 9.5$ , 6.5 Hz, 1H), 1.92–2.03 (m, 2H), 1.33–1.44 (m, 4H), 1.03–1.12 (m, 2H);  $^{13}\text{C}$  NMR (125 MHz,  $\text{CDCl}_3$ )  $\delta$  173.8, 160.0, 137.9, 133.9, 131.6, 129.8, 128.0, 127.3, 123.3, 113.6, 101.3, 98.8, 83.05, 74.58, 74.02, 69.59, 68.73, 66.10, 55.81, 55.27, 51.44, 33.67, 28.91, 25.24, 24.35; HRMS ( $M + \text{Cs}$ ) calcd for  $\text{C}_{36}\text{H}_{39}\text{O}_{10}\text{NCs}$  778.1628, found 778.1652.3). The product (2.7 g, 4.19 mmol) from step 2 was mixed with  $\text{NaCNBH}_3$  (1.38 g, 21 mmol), DMF (35 mL), and 3- $\text{\AA}$  molecular sieves (5.0 g), and a solution of trifluoroacetic acid (3.2 mL, 42 mmol) in DMF (25 mL) was added dropwise at 0 °C. The reaction mixture was stirred for 1.5 h at 0 °C and then 24 h at room temperature. After addition of further trifluoroacetic acid (3.0 mL) in DMF (20 mL), the reaction mixture was stirred for another 24 h at room temperature. The mixture was diluted with EtOAc (50 mL) and MeOH (5 mL) and filtered through Celite, and the cake was washed with EtOAc (150 mL). The combined filtrates were washed with cold water (200 mL), cold saturated  $\text{NaHCO}_3$  (200 mL), and brine (2  $\times$  100 mL) and dried over  $\text{Na}_2\text{SO}_4$ . The solvent was removed, and the residue was purified by column chromatography on silica gel (hexanes/EtOAc, 2:1) to give **56** (2.45 g, 90%) as an oil:  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$  7.68–7.81 (m, 4H), 7.28 (d,  $J = 8.5$  Hz, 2H), 7.04–7.06 (m, 2H), 6.92–6.96 (m, 3H), 6.89 (d,  $J = 8.5$  Hz, 2H), 5.12 (d,  $J = 8.0$  Hz, 1H), 4.75 (d,  $J = 12.0$  Hz, 1H), 4.57 (d,  $J = 11.5$  Hz, 1H), 4.53 (d,  $J = 12.5$  Hz, 1H), 4.51 (d,  $J = 11.5$  Hz, 1H), 4.21 (dd,  $J = 11.0$ , 8.5 Hz, 1H), 4.13 (dd,  $J = 11.0$ , 8.5 Hz, 1H), 3.81 (s, 3H), 3.73–3.82 (m, 4H), 3.60–3.64 (m, 1H), 3.59 (s, 3H), 3.35 (dt,  $J = 9.5$ , 6.5 Hz, 1H), 3.07 (d,  $J = 2.0$  Hz, 1H), 1.91–2.02 (m, 2H), 1.32–1.45 (m, 4H), 1.01–1.12 (m, 2H);  $^{13}\text{C}$  NMR (125 MHz,  $\text{CDCl}_3$ )  $\delta$  173.8, 159.3, 138.2, 133.7, 129.6, 129.4, 128.1, 127.8, 127.3, 113.9, 98.2, 78.55, 74.66, 74.20, 73.36, 73.36, 70.45, 69.18, 55.31, 55.20, 51.31, 33.60, 28.87, 25.17, 24.35; HRMS ( $M + \text{Cs}$ ) calcd for  $\text{C}_{36}\text{H}_{41}\text{O}_{10}\text{NCs}$  780.1785, found 780.1759.

**5-Methoxycarbonylpentyl 4-*O*-[3-*O*-(2,3,4,6-Tetra-*O*-benzyl- $\alpha$ -D-galactopyranosyl)-4-*O*-(2,3,4-tri-*O*-benzyl- $\alpha$ -L-fucopyranosyl)-2-*O*-benzoyl-6-*O*-*tert*-butyldiphenylsilyl- $\beta$ -D-galactopyranosyl]-3-*O*-benzyl-2-deoxy-6-*O*-*p*-methoxybenzyl-2-phthalimido- $\beta$ -D-glucopyranoside (57).** To a solution of the disaccharide **32** (15.0 mg, 0.01437 mmol) and the fucoside **50** (13.9 mg, 0.02155 mmol) in  $\text{CH}_2\text{Cl}_2$  (2 mL) was added 4- $\text{\AA}$  molecular sieves (300 mg), and the mixture was stirred for 20 min at room temperature under argon. A freshly prepared solution of DMTST from methyl disulfide (8.2 mg, 86.2  $\mu\text{mol}$ ) and methyl trifluoromethanesulfonate (14.3 mg, 86.2  $\mu\text{mol}$ ) in  $\text{CH}_2\text{Cl}_2$  (0.5 mL) was added to the above stirred mixture at 0 °C, and the progress of the reaction was followed by TLC. The reaction mixture was stirred at 0 °C for 30 min and at room temperature for 1 h, and then a solution of **62** (27.9 mg, 0.04311 mmol) in  $\text{CH}_2\text{Cl}_2$  (0.5 mL), NIS (5.1 mg, 0.02155 mmol), and TFOH (25  $\mu\text{L}$ , 0.3 M ethereal solution) were added. The reaction mixture was stirred for 30 min at room temperature and then quenched by adding  $\text{Et}_3\text{N}$  (0.8 mL), diluted with  $\text{CH}_2\text{Cl}_2$ , and filtered. The organic phase was successively washed with saturated aqueous  $\text{Na}_2\text{S}_2\text{O}_3$ ,  $\text{NaHCO}_3$ , and brine, dried over  $\text{Na}_2\text{SO}_4$ , and concentrated. The residue was purified by column chromatography on silica gel (hexanes/EtOAc, 3:1 to 2:1) to give product **57** (17.2 mg, 57%) as a thick oil:  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$  8.00 (d,  $J = 8.0$  Hz, 2H), 7.08–7.77 (m, 46H), 6.96–6.97 (m, 4H), 6.81–6.85 (m, 6H), 6.76 (d,  $J = 6.0$  Hz, 2H), 6.64 (t,  $J = 7.5$  Hz, 1H), 6.55 (t,  $J = 7.5$  Hz, 2H), 5.98 (d,  $J = 3.5$  Hz, 1H), 5.90 (dd,  $J = 10.0$ , 7.5 Hz, 1H), 5.28 (d,  $J = 3.5$  Hz, 1H), 4.94 (d,  $J = 8.0$  Hz, 1H), 4.88 (d,  $J = 12.5$  Hz, 1H), 4.83 (d,  $J = 7.5$  Hz, 1H), 4.81 (d,  $J = 11.5$  Hz, 1H), 4.78 (d,  $J = 11.5$  Hz, 1H), 4.64–4.71 (m, 2H), 4.59 (d,  $J = 11.0$  Hz, 1H), 4.55

(d,  $J = 12.5$  Hz, 1H), 4.54 (d,  $J = 12.0$  Hz, 1H), 4.45 (d,  $J = 11.0$  Hz, 2H), 4.43 (d,  $J = 12.0$  Hz, 1H), 4.27–4.36 (m, 6H), 4.17 (d,  $J = 12.0$  Hz, 1H), 3.98–4.09 (m, 5H), 3.93 (d,  $J = 12.0$  Hz, 1H), 3.85–3.90 (m, 2H), 3.73–3.80 (m, 5H), 3.57–3.68 (m, 5H), 3.56 (s, 3H), 3.51 (q,  $J = 6.5$  Hz, 1H), 3.36–3.42 (m, 3H), 3.19–3.27 (m, 4H), 1.84–1.96 (m, 2H), 1.25–1.35 (m, 4H), 1.10 (s, 9H), 0.95–1.03 (m, 2H), 0.90 (d,  $J = 6.5$  Hz, 3H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  164.43, 159.11, 139.45, 139.42, 139.17, 138.78, 138.66, 138.51, 138.17, 137.88, 135.69, 135.48, 133.53, 133.47, 133.00, 130.40, 129.82, 129.74, 129.33, 128.70, 128.53, 128.45, 128.38, 128.33, 128.24, 128.19, 128.15, 128.00, 127.87, 127.74, 127.69, 127.66, 127.51, 127.48, 127.22, 126.84, 126.58, 113.71, 100.44, 98.15, 94.78, 94.29, 78.72, 78.28, 77.22, 77.17, 76.51, 75.59, 74.97, 74.83, 74.69, 74.65, 74.50, 74.22, 73.44, 73.34, 73.03, 72.84, 72.07, 71.46, 69.75, 69.06, 68.97, 67.90, 66.64, 64.92, 63.76, 55.74, 55.24, 51.35, 33.69, 29.70, 28.83, 27.02, 25.27, 24.37, 22.69, 19.25, 16.84, 14.13; HRMS (M + Cs) calcd for  $\text{C}_{126}\text{H}_{135}\text{O}_{25}\text{NSiCs}$  2222.8147, found 2222.8294.

**5-Methoxycarbonylpentyl 3,4,6-Tri-O-acetyl-2-deoxy-2-phthalimido- $\beta$ -D-glucopyranoside (61a).** To a mixture of **60**<sup>25</sup> (30.0 g, 62.89 mmol) and methyl 6-hydroxylhexate (13.8 g, 94.3 mmol) in  $\text{CH}_2\text{Cl}_2$  (550 mL) was added  $\text{BF}_3/\text{OEt}_2$  (120 mL, 943 mmol) at 0 °C. After the reaction mixture was stirred overnight, water (15 mL) was added to the mixture. The mixture was diluted with  $\text{CH}_2\text{Cl}_2$  (400 mL), washed with saturated  $\text{NaHCO}_3$  (3  $\times$  200 mL) and brine (200 mL), dried over  $\text{Na}_2\text{SO}_4$ , filtered, and concentrated. The residue was purified by column chromatography on silica gel (hexanes/EtOAc, 2.5:1) to give **61a** (26.0 g, 73%) as a solid:  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$  7.84–7.89 (m, 2H), 7.73–7.77 (m, 2H), 5.79 (dd,  $J = 10.5, 9.0$  Hz, 1H), 5.36 (d,  $J = 8.5$  Hz, 1H), 5.18 (dd,  $J = 10.0, 9.5$  Hz, 1H), 4.34 (dd,  $J = 12.0, 4.5$  Hz, 1H), 4.31 (dd,  $J = 10.5, 8.5$  Hz, 1H), 4.18 (dd,  $J = 12.5, 2.5$  Hz, 1H), 3.81–3.89 (m, 2H), 3.61 (s, 3H), 3.44 (dt,  $J = 10.0, 6.5$  Hz, 1H), 2.12 (s, 3H), 2.04 (s, 3H), 1.97–2.07 (m, 2H), 1.87 (s, 3H), 1.37–1.51 (m, 4H), 1.04–1.18 (m, 2H);  $^{13}\text{C}$  NMR (125 MHz,  $\text{CDCl}_3$ )  $\delta$  173.8, 170.7, 170.2, 169.5, 134.3, 131.3, 123.6, 98.10, 71.79, 70.74, 69.73, 68.97, 62.00, 54.59, 51.38, 33.67, 28.84, 25.20, 24.37, 20.75, 20.57, 20.44; HRMS (M + Na) calcd for  $\text{C}_{27}\text{H}_{33}\text{O}_{12}\text{NNa}$  586.1900, found 586.1920.

**5-Methoxycarbonylpentyl 2-Deoxy-2-phthalimido- $\beta$ -D-glucopyranoside (61b).** Compound **61a** (26.0 g, 46.18 mmol) was treated with  $\text{NaOMe}/\text{MeOH}$  (25 wt %, 2.7 mL) in  $\text{MeOH}$  (200 mL) at room temperature. After 6 h, the mixture was neutralized (IRC-50 resin, weak acid) and concentrated to give product **61b** (20.0 g, 99%) as a semisolid:  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$  7.78–7.82 (m, 2H), 7.68–7.72 (m, 2H), 5.16 (d,  $J = 8.5$  Hz, 1H), 4.63 (d,  $J = 4.5$  Hz, 1H), 4.25–4.31 (m, 2H), 4.06 (dt,  $J = 2.0, 8.5$  Hz, 1H), 3.88–3.89 (m, 2H), 3.76 (dt,  $J = 10.0, 6.5$  Hz, 1H), 3.65–3.71 (m, 1H), 3.59 (s, 3H), 3.48 (t,  $J = 6.5$  Hz, 1H), 3.43 (dt,  $J = 9.5, 3.5$  Hz, 1H), 3.38 (dt,  $J = 10.0, 6.5$  Hz, 1H), 1.90–2.02 (m, 2H), 1.31–1.43 (m, 4H), 1.00–1.09 (m, 2H);  $^{13}\text{C}$  NMR (125 MHz,  $\text{CDCl}_3$ )  $\delta$  174.0, 168.4, 134.0, 131.6, 123.4, 98.31, 75.53, 71.53, 71.20, 69.43, 61.63, 56.66, 51.38, 33.65, 28.84, 25.18, 24.34; HRMS (M + Na) calcd for  $\text{C}_{21}\text{H}_{27}\text{O}_9\text{NNa}$  460.1584, found 460.1598.

**Mathematical Model.** So as to be able to analyze the problem of designing optimal syntheses of oligosaccharides with a computer, it was necessary to quantify the relationship between yield and relative rate constants for donors in the database. A short treatment for this problem is shown below. It gives the mathematical relationship between yield under optimal conditions (no side reactions, 100% reaction with promoter, etc.) and the relative rate ratio between the two donors being considered for each individual step.

**Relationship between Relative Rates and Substrate Consumption.** Assumptions: Each competing reaction can be described by a second-order rate equation:

$$\frac{\partial A_1}{\partial t} = -k_1[A_1][E] \quad \frac{\partial A_2}{\partial t} = -k_2[A_2][E]$$

(i) **Integrated Second-Order Rate Equation.** Solving for [E] over one of them and substituting into the other, one obtains

$$\frac{\partial A_1}{[A_1]} = \frac{k_1}{k_2} \frac{\partial A_2}{[A_2]}$$

This is then integrated over the bounds of the experiment:

$$\int_{[A_1]_0}^{[A_1]_t} \frac{\partial A_1}{[A_1]} = \frac{k_1}{k_2} \int_{[A_2]_0}^{[A_2]_t} \frac{\partial A_2}{[A_2]}$$

$$\ln[A_1]_t - \ln[A_1]_0 = \frac{k_1}{k_2} (\ln[A_2]_t - \ln[A_2]_0)$$

Finally,

$$\frac{k_1}{k_2} = \frac{\ln[A_1]_t - [A_1]_0}{\ln[A_2]_t - [A_2]_0} = \frac{\ln[A_1]_t/[A_1]_0}{\ln[A_2]_t/[A_2]_0} \quad (1)$$

(ii) **The Yield Equation.** Assumptions: All reacting starting material goes to product:

$$\frac{[A_1]_t}{[A_1]_0} = 1 - \frac{[P]_t}{[A_1]_0} \frac{[A_2]_t}{[A_2]_0} = 1 - \frac{[Q]_t}{[A_2]_0}$$

The two donors are present in equimolar concentrations:

$$[A_1]_0 = [A_2]_0$$

The only detractor from yield is competition from the undesired donor:

$$\text{yield} = \frac{[P]_t}{[A_1]_0} = 1 - \frac{[Q]_t}{[A_2]_0}$$

Borrowing eq 1 for the relationship between rate constant ratios and consumption of starting material, we can quickly use it to predict the production of the two products P (desired) and Q (undesired).

$$\frac{k_1}{k_2} = \frac{\ln[A_1]_t/[A_1]_0}{\ln[A_2]_t/[A_2]_0} = \frac{\ln(1 - [P]_t/[A_1]_0)}{\ln(1 - [Q]_t/[A_2]_0)} \quad (2)$$

Rearranging, we find that

$$\ln((1 - [Q]_t/[A_2]_0)^{k_1/k_2}) = \ln(1 - [P]_t/[A_1]_0)$$


$$(1 - [Q]_t/[A_2]_0)^{k_1/k_2} = 1 - [P]_t/[A_1]_0$$

Finally, employing the simple yield relations listed in the assumptions above, this becomes

$$(\text{yield})^{k_1/k_2} = 1 - \text{yield} \quad (3)$$

This is not directly solvable for yield. However, a computer can find the solution through a number of approaches involving iterative solution. The rest of us can simply refer to Figure 4 for the solution to this equation, which is possible to draw because eq 3 may be solved for  $k_1/k_2$ .

**Optimizer.** To search the library of donors for the combination of donors which produces the best possible yield, a computer program, OptiMer, was constructed using C/C++ using Metrowerks CodeWarrior Professional Release 3 to run on Macintosh PowerPC computers to identify sets of available donors which best satisfy the yield calculation shown in eq 2 above. The program interfaces with a database of donors stored using the FileMaker Pro 4.0. When the user signals his readiness to run a search, the C++ program loads the database and searches it to identify the 100 best sets of available characterized oligosaccharide donors. For large sequences, a Monte Carlo search method is also available, which simply picks combinations at random. The frequency with which each donor appears at each step in the list of the best 100 donor sets is tabulated, and the user is presented with a list of donors at each step which tend to give the highest overall yields. The user is then free to make an educated choice as to which donors to use on the basis of availability, cost, and donor reactivity.



**Figure 4.** Relationship between expected yield and the rate ratios between the donor and acceptor.

One potential limitation of this approach stems from the extremely dense information capacity inherent in the carbohydrate code.<sup>29</sup> This manifests itself as an extremely rapid increase in the computational burden with increasing library size and increasing number of monomer units in the oligomer. As a result, the following optimizations were made to the search logic: The program only checks donors for a reaction step which have a donor reactivity less than or equal to the reactivity of the donor used in the previous step. As a result, the program will return no result in which the reactivities of the donors do not decrease (or stay the same) over the course of the multistep reaction. In addition, the program (when not in Monte Carlo mode) checks the sequences in order of decreasing reactivity for the donor used in step one. If the program finds that a particular donor at step one yields no "hits" for all combinations of donors for steps which follow it, the program will not examine less reactive step one donors. This can be done because a more reactive step one donor will always give a better estimated yield than a slower one, provided the reactivities of the other donors are kept constant. For large libraries which are well represented for all values for most donors, there is an intelligent search option which further restricts the search at each step to the range of values around the expected optimal reactivity.

For a hexasaccharide search using a library with 200 random donors with reactivities ranging from 1 to 10 000 available for each step, the

(29) Laine, R. A. *Pure Appl. Chem.* **1997**, *69*, 1867.

normal set of optimizations reduces the number of sequences needed to be scanned from 320 billion to approximately 70 million (a factor of 4500). (The intelligent search further accelerates it by a factor of 3 or 4.) Given that current desktop computers manage about 200 million CPU clock cycles per second, searching the full sequence space even at one CPU cycle per sequence would require 15 min of search time. (The real number of cycles per sequence is orders of magnitude larger than that.)

OptiMer calculates the stepwise yield by minimization of an error function which is based on the yield equation (eq 3). This error function should have its minimum for values of yield and  $k_1/k_2$  which best satisfy eq 3, and it should always be positive, with a minimum of zero for  $0 < \text{yield} < 1$  (100%).

$$\text{error} = (\text{yield}^{k_1/k_2} + \text{yield} - 1)^2$$

An initial guess as to the correct yield value was obtained using a simpler stepwise yield equation which assumes first-order kinetics [ $\text{yield} = k_1/(k_1 + k_2)$ ]. This value was optimized by picking two yield values which are somewhat higher and lower than the original value and evaluating the error function for all three yield values. This provided three points (yield vs error for the given  $k_1/k_2$ ) with which to calculate a parabolic approximation of the error function ( $\text{error} = A + B(\text{yield}) + C(\text{yield}^2)$ ). From this, a better estimate for the yield can be directly obtained, based on the minimum of the parabolic function (minimum =  $-B/2C$ ). This was performed in an iterative fashion, in the process narrowing the bracketing outlying points and optimizing the yield value until the yield value had converged to stepwise changes of less than 0.00001%. The yield values so obtained were checked against eq 3 (which can be solved for  $k_1/k_2$ ) and were found to deviate from the expected value by no more than  $\pm 0.001\%$  over the range  $10^{-6} < k_1/k_2 < 10^6$ . Past this range, the yield is expected to be extremely close to 0% ( $k_1/k_2 < 10^{-6}$ ) and 100% ( $k_1/k_2 > 10^6$ ). Errors outside the tested range are expected to influence the overall yield calculation insignificantly, since the yield behaves asymptotically in these areas. The stepwise yields are multiplied together to obtain an overall calculated yield for the set of donors; if the overall yield is large enough to be included in the list of top hits, the set of donors is stored for later output to the user.

**Acknowledgment.** We gratefully acknowledged a fellowship (NATO-Postgraduierstipendium) granted by the DAAD to R.W. We thank Dr. Shuichi Takayama for helpful discussions and Dr. L. Taylor Ollmann for valuable and insightful discussions regarding the handling of eq 3.

JA982232S